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1.1 Transgenic mouse models
Mice are thankfully exploited to study biological processes that cannot be tested in a
petri dish and need to be studied in vivo in a real organism. Mice are not only used
because they are small, easy to handle, have a fast reproduction rate and are widely
available, but because mice and humans share about 97.5% of their DNA [1]. The
latter statement implies that many diseases in mice and humans have a similar form
of progression and show similar effects. Therefore, studying biological processes in
mice will give insight on human biological processes. A mouse is called ‘transgenic’ if
its genetic material has been altered, for instance by the introduction of human genes
into its genotype. The exploitation of transgenic mice for research of human diseases
is a world-wide debate, even though parallel to the development of transgenic mice,
ethical committees were set up everywhere to guarantee that all transgenic animal
research is performed under strict guidelines for health and wellbeing of the mice.
1.1.1 History
The first notice of mice appearing in the laboratory setting was around 1897, when
the Biologist William Haacke described the effect of heritage of the coat in albino
mice. Unfortunately his work is often overlooked because of his failure to supply
data [2]. Therefore, the first description of genetical heritage of the color coat in
mice is generally considered to be the work of the Frenchmen Lucien Cuenot, who
described recessive and dominant alleles. In 1909, Clarence Cook Little developed
the first inbred mouse strain to study their genotype in the hope that, one day, this
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would support research on human diseases, such as cancer. Later this mouse developed
into the C57BL mouse, which is now the most widely described and used genotype.
The first genetically modified mice were reported in 1974 by Jaenisch and Mintz [3].
They injected mouse embryos (blastocysts) with the Simian virus 40 (SV40) DNA,
a polyomavirus that has to potential to cause tumors, and showed that the mice
and their offspring had inherited the SV40 DNA in their DNA. But it was not until
1982 when Brinster and Palmiter incorporated the human growth gene to a mouse
model [4], that the clinical world could see the enormous advantages of exploiting
transgenic mouse models for human genetic studies.
Since the early 80s, the development of standardized mouse strains (groups of
mice with identical genotype) for biomedical research has expanded tremendously.
Currently mouse models are available for a whole range of human diseases. Also,
standardized mouse atlases were created which contain a complete set of images that
have a full description of the anatomy visualized. This information is worldwide used
as reference, for validation purposes and as guideline for the interpretation of one’s
own findings. Digital mouse atlases are currently available for the brains [5–11], the
limbs [12] and even the whole body [13,14].
1.1.2 Generation of transgenic mice
There are several ways to modify the genotype of mice [15, 16]. Here the two most
common techniques are shortly explained:
Microinjection
The female reproductive cells, the oocytes are harvested mixed with sperm from the
male and in a petri dish. After one spermatozoon has entered the oocyte, it takes a
few hours before the pronuclei of the two cells fuse and become a so-called zygote. In
that period, the linear DNA sequences of the foreign genes are typically injected by
microinjection into the male pronucleus [17]. For a microinjection, special needles and
cell-holders are used which are roughly 0.5 - 5 µm in diameter (see figure 1.1 ). After
the microinjection, the oocytes are placed into the uterus of a pseudopregnant female
mouse. If the integration of the gene with the DNA was successful, the offspring will
express the new gene.
Injections of embryonic stem cells
A blastocyst is the very first stage of the embryo, consisting of a group of cells that will
later form the embryo (embryoplast) surrounded by an outer layer of cells that will
become the placenta (trophoblast). Cells that are taken out from the embryoplast
are called stem cells and have to capability to develop themselves into almost any
type of tissue. The DNA of these cells can be modified with high precision and will,
depending on the technique, result in knock-out, knock-in or conditional mice [18].
After modification of the gene, the genetically modified embryonic stem cells are
placed back in the embryoplast by microinjection. Now, the cells will behave exactly
as the other cells in the embryo, resulting in a chimera mouse (figure 1.1), where the
phenotype expresses a mixture of the modified genotype and the normal genotype,
depending on which cells were descendants of the modified stem cells and which were
2
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not. If the embryonic stem cells have contributed to the germ cells of the chimeras,
then their offspring will all express the gene. The chimera mouse is mated with a
mouse with the normal genotype, a so-called wildtype, half of their offspring will be
heterozygous for the modified gene and the rest are wildtype mice. The offspring of
the heterozygous mice results in mice that are either wildtypes, heterozygous for the
modified gene, or homozygous for the mutated gene. The mice in the latter group all
express the gene and will pass it on to their offspring, allowing a reliable production
of genetically modified mice.
1.2 Mouse brain anatomy
The mouse brain is considered a valid model for human brain diseases [19, 20], since
all brain structures that occur in the human brain are also present in the mouse brain
and they are similarly connected to each other, although differently organized and in
different volume proportions. Especially human neurophysiology and neuropathology
can be well studied in mouse models [21, 22]. Human psychiatric disorders are less
commonly studied as the cerebral cortex of the mice is not as highly developed as
in humans [23]. Figure 1.2 displays a comparison between the human brain and
the mouse brain, where a volume rendering of the whole brain (A) shows the lack of
cortical folding in mice and a slice through both brains (B) shows a few corresponding
brain structures.
1.3 High resolution magnetic resonance imaging
Due to the increasing amount of applications for transgenic mice, small animal devices
are being developed that are capable of imaging at high resolutions (∼ 10-50 µm).
For magnetic resonance imaging (MRI), this resulted in scanners with a high mag-
netic field, from 7 T, 9.4 T up to 17 T. MRI is a highly suitably imaging modality
for brain imaging, as it is not based on ionizing radiation and therefore not damaging
for the subject and it can acquire the images in vivo as well as ex vivo. Furthermore,
MRI allows the acquisition of functional and anatomical scans with a wide range of
imaging protocols all giving different information of the brain. The most commonly
used imaging protocols for mouse brain imaging are:
T1-weighted imaging
This protocol with long repetition times (TR) and short echo times (TE) has low
contrast between gray and white matter, and is typically used with contrast agent,
for example to visualize the vessel structure.
T2-weighted imaging
This protocol has short repetition times (TR) and long echo times (TE), resulting in
a relatively high contrast between gray and white matter and is therefore excellent
for anatomical imaging of the brain.
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Figure 1.1: The process to generating transgenic modified mice through the implan-
tation of embryonic stem cells, see section 1.1.2 for further details. Photography
courtesy of Anne Bower and Manfred Baetscher, Transgenic Core, Oregon Health &
Science University, Portland, OR. Printed with permission.
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Figure 1.2: Comparison between the mouse brain and the human brain A) the outer
surface and B) the internal anatomy.
Blood-oxygen-level dependence (BOLD) imaging
Protocol for BOLD imaging is sensitive for changes in the concentration of oxygenated
hemoglobin, which will occur if a certain part of the brain has higher activity and
requests an increased blood supply. Therefore, this technique is very suitable for
functional imaging.
Diffusion tensor imaging
This protocol measures the diffusion of water in tissue. In brain tracts, the diffusion
of water usually follows the direction of the tract and therefore, with diffusion tensor
imaging the direction of the brain tracts can be visualized in high detail.
1.4 Aim of the thesis
To study the diseased brain, it is important to quantify local changes in the brain
that occur as a result of the disease. The study of global or local shape variations
in the brain is also defined as brain morphometry. In human brain MRI, automation
of the morphometry process has already guided researchers to new insights regarding
the (diseased) brain. With the development of MR systems for animal models, it is
5
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now possible to acquire detailed anatomical in vivo images that offer the possibility
to perform in vivo morphometry on the rodent brain. However, extending automated
methods developed for human MRI to mouse brain MRI is not as trivial as it seems.
This thesis explores the possibilities for automated morphometry on MR images of
mouse brains. The main contributions of this work are (a) to investigate the methods
currently applied for quantitative morphometry in mouse brain MR images and (b) to
provide analytical tools that can be used for the automated quantitative morphometry
of mouse brains. Each chapter in this thesis is self-contained and therefore, some
overlap between the chapters occurs.
1.5 Thesis outline
First, the topic of morphometry is introduced in chapter 2 and an overview is given
of the various morphometry methods and trends that are available for mouse brain
MRI analysis. Furthermore, it is discussed which method is the most suitable for
which situation and what the limitations and attention points are for automated
morphometry. Chapter 3 describes an application of automated morphometry on
Alzheimer’s Disease (AD) at an early stage in transgenic mouse brain MRI, it reviews
(automated) methods in the literature. The most common transgenic mouse strains
for AD are introduced, the several MR imaging parameters to detect plaques in the
brain are discussed and an overview of the currently available automated methods
capable of detecting AD is given.
As volumetry is the first step in quantitative morphometry, chapter 4 presents
an automated segmentation method for in vivo and ex vivo MRI, based on a hybrid
method of affine registration and clustering. This clustering method is compared
to manual segmentation and segmentation by nonlinear registration to evaluate its
performance.
Automated morphometry is continued in the direction of deformation-based mor-
phometry. Chapter 5 presents the generalized Moore-Rayleigh test that tests high-
dimensional vector fields for spherical symmetry and shows on simulated data how
this nonparametric test can be applied to detect local brain differences between groups
of transgenic mice. In chapter 6 the Moore-Rayleigh test is further explored on ex-
perimental data of AD transgenic mice. Using synthetical and clinical data we show
that the performance of the Moore-Rayleigh test outperforms the classical permuta-
tion test and significantly lowers the computational time as it is not dependent on
the randomization of the data. In chapter 7, a clinical application of the Moore-
Rayleigh test is shown in parallel with a volumetry study to phenotype a transgenic
mouse model that exhibits migraine.
Chapter 8 and 9 conclude this thesis with a summary and indications for further
research in English and Dutch, respectively.
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Morphometry on rodent brains
A.E.H. Scheenstra
J. Dijkstra
L. van der Weerd
This chapter was adapted from:
Volumetry and other quantitative measurements to assess the rodent brain, In vivo
NMR Imaging: Methods and Protocols. Humana Press, USA. Ed. C. Faber and
L. Schroeder. in press.
Chapter 2
Abstract: Morphometry is defined as studying variations in
shapes and the detection of possible shape changes between groups.
Evaluation of shape changes in the brain is a key step in the devel-
opment of new mouse models, the monitoring of different patholo-
gies and the measuring of environmental influences. Traditional
morphometry was performed by volume measurements on manual
shape delineation, the so-called volumetry. Currently, automated
methods have been developed that can be roughly divided in three
groups; voxel-based morphometry, deformation-based morphome-
try and shape-based morphometry. In this chapter we describe the
different approaches for quantitative morphometry and how they
can be applied to the quantitative analysis of the rodent brain.
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2.1 Introduction
MRI of the brain is increasingly used for standard phenotyping of transgenic mouse
models, or for non-invasive monitoring of disease progression and treatment response.
Quantitative analysis of the brain images is also referred to as brain morphometry,
which is derived from the Greek µo%φ (shape or form) and µετ%oν (measurement)
and is defined as studying variations and changes of different structures in the brain.
The main research question in brain morphometry is how to determine significant
differences between two groups of rodents, i.e. how to determine the brain shape
differences between two groups of mice that are not the result of inter-subject variation
in the brain, but caused by the differences between the two groups. For example, a
diseased and a healthy group, or one group of rodents followed over time and measured
at multiple time-points.
2.2 Volumetry
In mouse studies volumetry is traditionally the standard method to perform brain
morphometry and is done by measuring the volume of the structure of interest (SOI)
by delineation. Therefore, this method is often used as the gold standard in the presen-
tation of new morphometry methods. In volumetry, a structure is delineated, either
manually or automatically [24] and that segmentation is used to calculate the volume.
The volume of each segmented structure is calculated by multiplying the number of
voxels in the structure with the volume of a voxel. Since mice with larger brains have
larger brain structures, the volumes are usually normalized to a percentage of the
total brain volume before the comparison between mice can be made. Furthermore,
partial volume effects will occur and therefore, volume calculation of small structures
will be less accurate than that of large structures. The advantage of this method
is that simple image processing methods are sufficient to perform volumetry, even
though volumetry doesn’t give any insight into how the shape changes.
2.3 Automated morphometry
This relatively new field of research analyzes the brain images locally to determine
where precisely the two brain shapes differ from each other. Although the automated
morphometry methods differ in the way the data is analyzed, the image processing
pipeline is similar for all methods, and can be described by the following steps:
1. Describe the SOI by its features, such as the outer boundary of the structure
being defined by landmarks or segmentation, intensity value, etc.
2. Extract these features for all images in the different treatment groups
3. Statistically test the features for a significant difference between the groups.
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4. Present the results by means of a Statistical Parametric Map (SPM), which
indicates local significance per voxel or reference point (Examples are shown in
figure 6.6 and figure 7.3.
5. Possibly apply a multiple test correction (see appendix 2.A)
Based on their feature selection, the morphometry methods can be roughly divided
into three groups; 1) Voxel-based morphometry (VBM) which calculates the gray and
white matter density for each voxel and uses that for further analysis, 2) deformation-
based morphometry (DBM) which warps all images to a standard reference and uses
the resulting deformation fields for the analysis, and 3) Shape-based morphometry
(SBM) which defines the shape based on the contour or landmarks. In this section
the principles of each method are discussed.
2.3.1 Voxel-based morphometry
In VBM, the mouse brains are normalized to a reference image. A very smooth (not
too accurate) non-linear registration step is applied for a better fitting of the brain
structures to the template. The non-linear registration should to be smooth enough
to bring homologous regions as close together as possible, but not too accurate in
order to avoid the homologous regions becoming identical. Afterwards the individual
brains are segmented using a probabilistic method into different structures of interest
based on the image intensity; thus each voxel is labeled with a posteriori probability
of belonging to gray matter, white matter or cerebrospinal fluid. Statistical analysis is
performed by applying a general linear model to retrieve a statistical parametrical map
[25]. Incorporating a GLM has the advantage that covariates and confounders (e.g.
age and total brain volume) can also be incorporated. The multiple-test correction
which is applied in the software is based on the random-field theory [26]. The free SPM
software package [27] is specially designed for voxel-based morphometry of human
brains, and has lately been extended with a special module for rodent brains [28].
2.3.2 Shape-based morphometry
SBM is currently mainly applied to human brains [29–31] and is added to this chap-
ter to complete the overview of possible methods. This method is especially useful
to assess local changes within structures of interest, e.g. in the case of enlarged ven-
tricles, to assess which parts of the ventricles are most affected [29]. To perform
SBM, all structures are normalized to a standard reference image to correct for global
brain size differences and brain orientations. Afterwards the SOI is segmented, either
manually or automatically; only the surface of the brain structure is considered for
further analysis of this segmentation. The surfaces are compared to each other using
reference points and/or anatomical landmarks; these points need to be at the exact
same anatomical locations.
In case of a local group difference, the spatial point clouds will differ between
groups and that can be tested for significance with a statistical test, e.g. permutations
10
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of a 3D Hotelling’s T 2 test and displayed in a SPM. Multiple test correction is required
before any conclusion on the whole brain structure can be made.
2.3.3 Deformation-based morphometry
The name of DBM refers to the nonlinear (deformable) registration which is applied
before the morphometry. Another term which is used within this framework is Tensor-
based morphometry (TBM). The difference between TBM and DBM is found in the
method of statistical analysis. To look for local differences in brain volume or shape,
DBM uses the deformation vectors directly as they are obtained from the nonlinear
registration of brain images, whereas TBM examines the Jacobian determinant (the
spatial derivative of the deformation fields) and uses that for the statistical analysis.
For both TBM and SBM, a normalization step is applied that globally registers the
brains to a standard reference brain, the target image. Afterwards a nonlinear regis-
tration is applied in such way that the source image is warped exactly onto the target
image. The resulting deformation field shows locally the changes that the source im-
age had to undergo to fit the target, thereby indicating the differences between the
source and target. The chosen registration method has to be as accurate as possible
and preferable diffeomorphic [32–34], which means that the registration method tries
to preserves the biological shape. Statistical analysis of the vector fields is performed
by:
Direct comparison (the DBM methods)
Statistical analysis is performed on the features that are directly taken from the
vectors, e.g. their magnitude [35], or their vector length and direction [36] (this
thesis).
Jacobian Calculation (The TBM methods)
The Jacobian is calculated from the deformation vectors, which is a measure of the
volume changes produced by a deformation. If the determinant of the Jacobian has
a value between 0 and 1, there is possible shrinkage of the tissue, if it is larger than
1 there is an increase of tissue volume. If the determinant of the Jacobian results
in a negative value then there is a biologically impossible deformation. A SPM is
obtained directly by applying a statistical test or by incorporating the deformation
field into general linear models that also model the global variables, such as gender and
age [37–39]. Another option is to use the volumetric changes to perform volumetry
measurements of a complete structure [40].
2.4 Method comparison
The described methods are all suitable for quantitative morphometry. All methods
have been standardized by using automated normalization and segmentation accord-
ing to an imaging processing pipeline and are, therefore, in principle unbiased for
brain size and observer. Furthermore, all automated methods are testing each voxel
separately for significant differences and are thus capable of producing an SPM. An
11
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overview of the characteristics of the methods is given in the table 2.1.
The differences between the methods determine the choice for which quantitative
morphology method is most suitable for the performed study. If a segmentation of the
SOI can be easily obtained by computer algorithms or by manual delineations, one
may consider SBM or volumetry. Volumetry is a good option if the research question
is only to detect SOIs that are significantly different between two groups. If a local
effect in the brain structure is expected, SBM may be considered as it returns locally
significant differences on the surface of the structure.
VBM and DBM are both capable of analyzing the whole brain, which is very suit-
able for general phenotyping. The choice between VBM and DBM is more subtle and
is dependent on the method available in the lab and the preference of the researcher.
Both methods produce an SPM, both need smoothing to handle noise in the images,
both need a perfect normalization to avoid improper conclusions and both allow the
usage of general linear models for the incorporation of global parameters. However,
VBM is based on a segmentation which defines composition of brain tissue in amounts
of grey matter and white matter and cerebrospinal fluids, whereas DBM uses the voxel
intensity range as input for the nonlinear registration. The use of deformation vectors
allows DBM to perform multivariate statistics per voxel, where VBM applies univari-
ate statistics. Univariate statistics are less realistic, as they consider only one voxel
at a time without the interaction with its neighbors. However, VBM is available as a
ready to use software package [27], whereas DBM is only available as free code [36].
Property volumetry VBM SBM DBM
Automated – X X X
analysis per structure X – X –
full brain analysis – X – X
statistical parametrical map – X X X
normalization required – X X X
segmentation required X X X –
multi-variate analysis – – X X
Ready to use software X X – –
Table 2.1: An overview of the characteristics between the four morphometry methods.
2.5 Limitations to automated morphometry
Automated image processing methods are developed to save time during the anal-
ysis, to have a more robust overall performance, i.e. reducing observer variability,
and to perform more and complicated analyses: it therefore allows analyses which
are impossible to perform by hand. But for automation to work properly, a fixed
12
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(imaging) protocol is required as unexpected artifacts may influence the results of the
automated method. For instance, the excision of a mouse brain in ex vivo brain MRI
causes to large deformations in the brain that are many times larger than the expected
in vivo shape variations between subjects [6]. Furthermore, automated methods rely
on reference images, and are optimized for a certain contrast (e.g. T1-weighted or
T2-weighted scans). Unexpected input, like a different orientation, or a slightly dif-
ferent scan protocol, or an update in the MRI scanner software may seriously hamper
automated analysis. Since animal MRI is still in development, researchers and MR
system developers tend to change imaging protocols continuously in order to optimize
image quality. This is one of the reasons why automated analysis is not as readily
and frequently used in small animal research as in clinical settings.
Interpretation of morphometry results must be performed prudently. If a signifi-
cant difference has been detected, it actually implies a significant difference in intensity
between the two groups. This can be due to a morphological difference between the
structures of the two groups or it can be caused by one or more errors during the
image processing. Since each of the pre-processing steps in the automated morphom-
etry method such as normalization, segmentation and/or non-linear registration to a
reference image may all introduce errors leading to a significant result [41,42]. There-
fore, if a significant difference is detected the raw data, the automated segmentations,
and the registered data have to be cross-checked carefully to determine whether the
significant effect can be explained by other causes than shape differences. A complete
guideline for reporting VBM studies, which is also applicable for SBM and DBM
methods, has recently been published [43].
2.A Multiple-test correction
In most automated quantitative morphometry methods a certain hypothesis about
group difference is tested for each voxel separately resulting in a p-value for each
voxel. All these tests are, unless otherwise specified, independently performed tests.
If a general conclusion on the brain is made instead of several conclusions for
individual voxels, Multiple-test correction is required [44]. Multiple-testing refers to
the testing of more than one hypothesis at the same time, where each test has its
own error margin. Combining these independent tests without correction results in
unacceptable error margins.
Example 1. 2 groups of brain MR images from the same population are tested for
group difference. The MR images have a 256Ö256Ö128 volume with 8,388,608 voxels.
If all hypotheses are tested with α = 0.01, on average 83,886 incorrect rejections of
the null-hypotheses might appear by chance and thus 83,886 voxels are considered
incorrectly as significantly different. If we don’t correct for this effect we might draw
the conclusion that groups from the same population are significantly different.
Multiple-test correction can be performed in several ways, of which the following




This is the most stringent and most straightforward correction. Bonferroni multiple-
test correction avoids false rejection of the null-hypotheses with a probability of α,
but thereby severely increasing the chance of a type 2 error (false negatives). To
correct for multiple-tests with Bonferroni, the null hypothesis for each voxel should
be rejected if (α/n) ≤ 0.01, where n is the number of tests (which equals the number
of voxels in the MR volume that is analyzed). This test is the best method for
truly independent voxels, although for brain morphometry Bonferroni correction is
usually too conservative, as the voxels in the brain usually are correlated with at least
neighbor voxels.
Random field theory
As Bonferroni correction is too conservative for locally dependent voxels, random
field theory is used to determine clusters of dependent voxels so that multiple-test
correction is only applied on the clusters instead of the voxels. This method requires a
smooth SPM, which means that its value changes gradually without sharp transitions
of probability values.
Resampling
The resampling method uses permutation tests to determine the corrected p-values.
A permutation test iteratively randomizes the two groups and tests if the original
situation is significantly different from the randomized groups [46]. In general, this
method has a high accuracy higher than the random field theory, but the resampling
method is computationally much more expensive than the Bonferroni correction and
the random field theory correction.
False Discovery Rate
The false discovery rate (FDR) is defined as the ratio of expected false positives in the
test [47] which can be used to threshold the SPM [48]. Since it is as straightforward
as the Bonferroni correction, but less conservative, it is often applied to multiple-test
correction. However, recently it has been shown that the FDR rate cannot be directly
used for voxel-based morphometry studies [49,50]
14
CHAPTER 3
Prospects for early detection of Alzheimer’s disease from serial









This chapter was adapted from:
Prospects for early detection of Alzheimer’s disease from serial MR images in trans-
genic mouse models. Current Alzheimer research. 2009;6(6):503-18.
Chapter 3
abstract: The existing literature on the magnetic resonance
imaging of murine models of Alzheimer’s disease is reviewed. Par-
ticular attention is paid to the possibilities for the early detec-
tion of the disease. To this effect, not only are relaxometric and
volumetric approaches discussed, but also mathematical models
for plaque distribution and aggregation. Image analysis plays a
prominent role in this line of research, as stochastic image models
and texture analysis have shown some success in the classification
of subjects affected by Alzheimer’s disease. It is concluded that
relaxometric approaches seem to be a promising candidate for the
task at hand, especially when combined with sophisticated image
analysis, and when data from more than one time-point is avail-
able. There have been few longitudinal studies of mouse models
so far, so this direction of research warrants future efforts.
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3.1 Introduction
Alzheimer’s disease (AD) is an age-related neurodegenerative disease characterized
by structural brain changes and cognitive dysfunction. Due to the aging in west-
ern societies, AD will pose a large psychological and economical burden in the fu-
ture [51]. Early detection of AD is therefore of considerable interest, since pharma-
cological treatment can reduce the amyloid burden and atrophy of the brain [52, 53].
The atrophy in the brain causes structural changes, which are detectable by various
non-invasive imaging modalities [54, 55] and such considerations have led to the de-
velopment of new imaging methodologies, for example diffusion-weighted magnetic
resonance (MR) imaging [56, 57] multiphoton microscopy [58] or positron emission
tomography [59].
The detection of AD by MR imaging techniques [60] is conveniently studied in
standardized mouse models [61–67]. Brain mapping techniques [68] can be used to
quantify changes, for example in voxel-based morphometry [27,69], and more involved
approaches estimate diffeomorphic changes in local brain structure [70] or construct
local surface models [31] from volumetric measurements. Texture analysis is an inter-
esting alternative [71] that has received little attention so far. The statistical analysis
of MR images allows to discriminate between disease conditions [35, 72]. However,
these analyses are often static, and do not usually incorporate knowledge about dis-
ease dynamics, molecular mechanisms [73,74] or structural changes in time. The latter
can in fact be inferred from longitudinal studies [75, 76], whereby animal models are
employed favorably [77,78].
Many extensive review papers have been written on Alzheimer’s disease in the past
[65,79–84]; it is not our intention to duplicate previous efforts. However, most reviews
on AD concerned with small animal imaging focus on the development of mouse
models or different scanning protocols to visualize plaques. In this paper we review the
existing work on early detection of AD from serial MR images of transgenic mice, with
special regard to the integration of dynamical information, i.e. how does (a) knowledge
about AD dynamics from longitudinal studies, (b) knowledge about developmental
changes in brain structure and (c) knowledge about disease processes at the molecular
level help in the detection process? In particular, statistical and quantitative image
analysis methods are addressed, and we subdivide them into volumetric approaches,
relaxometric approaches, methods based on plaque burden evaluation, and methods
based on texture analysis. Finally we give some recommendations for further research,
by indicating gaps in the literature, interesting research directions and problems still
to be solved.
3.2 Alzheimer mouse models
Several of the genes involved in the development of familial AD have been isolated in
human studies. These genes have been used to develop a wide variety of transgenic
mouse models, all displaying one or more of the characteristic pathological features
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of the disease [79]. The most common lesions are schematically depicted in figure 3.1:
Senile plaques arising from amyloid-beta (Aβ) accumulation and inflammatory pro-
cesses involving glial cells, neurofibrillary tangles (NFT) involving tau protein from
the cytoskeleton of affected neurons, and vascular lesions caused by amyloid-beta de-
posits in cerebral arteries. The characteristics of several lines of transgenic mouse
models [85–106] is given in table 3.1. A more extensive description of these lines is
given in Appendix 3.A. Not all available mouse models are described, but those mod-
els which have either significantly advanced the understanding of AD pathogenesis
or are otherwise in widespread use. This overview is adapted from the work of Mc-
Gowan et al. [82], and expanded upon with information obtained from the Alzheimer
Research Forum1.
Figure 3.1: Pathological features of Alzheimer’s disease: Normal neuron and synapse
(A). Affected neuron in late-stage (B). Normal cerebral artery (C). Affected cerebral
vessel (D).
The work of Benveniste et al. [62] showed in 1999 that it is possible to visual-
ize plaques in ex vivo samples of human brain by means of MR imaging. In vivo
imaging of plaque deposition in human brains has so far not been successfully im-
plemented. Visualization of plaques in mouse models at high field strengths has
been successful, with first in vivo results reported in 2003 by Wadghiri et al. [107].
Since then, several groups have attempted to visualize plaque burden in vivo in dif-
ferent transgenic strains of mice, both with and without the aid of contrast agents.
Furthermore, the development of plaques with age in individual mice has been suc-
cessfully tracked using in vivo high resolution magnetic resonance imaging [77]. To
date, the most commonly used AD models in this line of MRI research are doubly
transgenic APP/PS1 strains [64–67, 78, 107–113], followed by singly transgenic APP
strains [67,77,78,107,114,115]. PS1 mouse models are occasionally used as controls,
1http://www.alzforum.org/res/com/tra/
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in addition to non-transgenic animals, as these animals have elevated Aβ levels, but
no Aβ deposits.
3.3 Relaxometry
In addition to anatomical or pathological features, several intrinsic MR parameters
can be studied to determine the effect of disease progression. In relaxometric ap-
proaches, the T1 (longitudinal, or spin-lattice) and T2 (transverse, or spin-spin) re-
laxation rates are commonly studied to facilitate the quantification of disease pro-
cesses. T1 specifies the rate at which the net magnetization returns to its equilibrium
state along the axis of the magnets bore, while T2 specifies the rate at which the net
magnetization in the transverse plane returns to zero after RF excitation. Alternate
relaxation parameters are T2* and T1rho. Unlike T2, the parameter T2* is influenced
by magnetic field gradient inhomogeneities and its relaxation time is shorter than
the T2 relaxation time. The spin lattice relaxation time constant in the rotating
frame, T1rho, determines the decay of the transverse magnetization in the presence of
a ”spin-lock” radiofrequency (RF) field [64].
Since both T2 and T1 relaxation times are sensitive to changes in biophysical
water content it has been hypothesized that the presence of Aβ deposits in the brain
has an effect on these parameters [110]. As such they might be used as independent
markers for changes occurring in tissue, averaged over a region of interest (ROI). In
fact, even pathological changes below the MRI resolution, i.e. at the subvoxel level,
could in principle be detected, as parameter values of a single voxel are the result of
an averaging process (partial volume effect). Several groups have studied the effects
of the progression of AD on the transverse relaxation rate T2; there is a general
consensus that the T2 values of affected brain tissue are lower than in controls, and
decrease further as AD progresses [77,78,109,110].
The analysis of relaxometric data in murine models of AD was first reported by
Helpern et al. in 2004 [110]. In their work APP/PS1 mice were compared to PS1 mice
and non-transgenic littermates. T2 values were found to be significantly lower in the
cortex, hippocampus and corpus callosum, when comparing doubly transgenic animals
to PS1 and non-transgenic mice, but T1 values did not show significant differences
between the three genotypes. Falangola et al. [109] studied APP/PS1, PS1 and non-
transgenic mice at two different ages. In addition to reporting a decrease in T2 in the
APP/PS1 mice, compared to the others, the authors performed image registration
to correctly compare specific regions of the brain between the different mice and
age groups. In the study by Vanhoutte et al. [115] T2* values were calculated for
the cortex and thalamic nuclei in APPV717I mice, which were compared to values
in wild type mice. T2* values in the cortex were found to be the same in both
groups, but decreased in the ventral thalamic nuclei of transgenics. Braakman et
al. studied Tg2576 mice and non-transgenic littermates, starting at 12 months and
following them until the age of 18 months [77]. The average T2 values in the cortex
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decreases of T2 were not observed in controls. Borthakur et al. studied T1rho values
in the cortex, hippocampus and thalamus of APP/PS1 mice and controls at ages 6, 12
and 18 months [64]. T1rho values decreased in both the transgenic and nontransgenic
groups as age increased, however the decrease was significantly more pronounced
in the transgenic animals. El Tannir El Tayara et al. studied both T1 [117] and
T2 [117,118] relaxation rates in APP/PS1 mice, with PS1 animals serving as controls.
They found that T2 values in the subiculum of adult APP/PS1 mice were significantly
lower than in PS1 mice and could thus serve as an early marker. Young mice (16-
31 weeks) without histochemically detectable iron showed T2 changes, which may
indicate that T2 variations can be induced solely by aggregated amyloid deposits.
Falangola et al. studied the changes of T2 in a large group consisting of APP/PS1,
APP, PS1 and non-transgenic controls [78]. This study revealed that only the APP
and APP/PS1 groups show significant changes in T2 compared to non-transgenic
controls. Table 3.2 presents an overview of relaxometric research in AD mouse models.
The statistical analysis of relaxometric data in its simplest form is based on sum-
mary statistics over a region of interest (ROI), which is usually much larger than the
resolution achieved, encompassing a number of voxels on the order of ten or more. To
compare the values of these variables between subjects and over the course of time (in
one or more subjects), the images need to be registered with respect to each other.
Between groups of subjects affected by AD and control subjects, there exist significant
differences between relaxometric rates. P -values can be derived from the empirical
standard deviation by assuming normality of the underlying population and relating
this to Student’s t-distribution. Given a large enough population one can even analyze
the dependence of the relaxometric data on further parameters, for example gender
or behavioral data, by the more general analysis of variance (ANOVA) or general lin-
ear models. However, the assumption of normality can be problematic, especially for
the limited number of mice usually included in the studies under review [119]; so one
better resorts to nonparametric tests such as the Mann-Whitney U test or the compu-
tation of Spearman’s rank correlation coefficient. If three or more time points exist,
linear regression is usually used, but nonparametric, nonlinear techniques can be more
powerful. Permutation tests, in particular, allow the computation of exact p-values
for the hypothesis that the summary statistics change in the course of time [120]. To
our knowledge, the latter has not yet been applied to the analysis of relaxometric
data of AD. Of course, suitable generalizations of ANOVA and linear regression also
exist, in the form of generalized linear models (GLM) or mixture models [121,122].
Ultimately, i.e. for a successful clinical application, the detection of AD should be
so robust, and the signal-to-noise ratio so large, that the correct choice of statistical
model will be largely irrelevant. At present, however, and especially in the analysis of
longitudinal studies, the choice of a correct statistical model is important to increase
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3.4 Analysis and models of plaque burden
Ever since Hardy and Higgins stated that the development of Aβ plaques is the main
cause of Alzheimer’ disease, leading to neurofibrillary tangles, cell loss, vascular dam-
age, and finally resulting in dementia [123]; this theory has been discussed and sup-
ported by other findings [124–126]. As mentioned before, the development in plaque
burden is still acknowledged as the primary biomarker of Alzheimer’s disease. As
Zhang et al. [67] showed, comparing histologically stained plaques with microimaging
data (8-24 hrs acquisition time), senile plaques can in principle be reliably identified
in ex vivo T2-weighted MR images. However, numerous smaller plaques were not
identifiable by visual inspection of the MR images. Later studies have shown that in
vivo and ex vivo visualization of both individual plaques and total plaque load can
be achieved by MR techniques in reasonable scan times without the aid of contrast
agents [64–66,77,110–113,115,127–129]. An overview of the relevant studies of plaque
burden in murine brain tissue is shown in Table 3.3.
In general, amyloid plaques are only visible on MRI scans in the later stages of
the plaque development. For example, plaque sizes in 12 month old APP/PS1 mice
are 19 µm on the average [130, 131], whereas the average voxel size in a MRI slice
is around 50Ö50Ö200 µm, which is further discussed in [63, 111, 127]. Therefore,
automated, direct detection and analysis of amyloid plaques on MRI scans is useful
for analyzing the progression of amyloid deposition, but it cannot be used for early
detection algorithms. Of course, indirect detection is still a possibility, since small
changes in tissue formation are detectable with the MRI scanner because of the partial
volume effect: insufficient image resolution leads to a mixture of the MR parameters of
different tissues within a single voxel. In other words, plaques influence the recorded
average relaxation rate per voxel proportionally, even in the case that the amount of
amyloid deposition is smaller than the sampling volume per single voxel. However,
a specific threshold in size for a plaque to be detectable at a prescribed confidence
level is not known at present. The analysis of plaque burden by direct imaging could
contribute to the latter by supplying the necessary data to set up a more sensitive
parametric image model. To this extent, plaque burden analysis has focused on the
statistical properties of senile plaques.
In principle, the locations at which plaques appear can be statistically modeled
as a spatial point process [132,133]. However, plaques are spatially extended objects
that aggregate, grow and change their shape over the course of time. Stanley and
co-workers therefore considered plaques as connected clusters and have found that the
cluster sizes in AD human patients follow a log-normal distribution [133]. Moreover,
they analyzed the spatial correlation function C(r), i.e. the (normalized) probability
of finding another plaque cluster at a distance r from a given cluster [74]. Comparison
with randomized surrogate data allowed them to define a characteristic cluster size
that changes from about 14 µm at 8 months to 22 µm at 12 months. Moreover, the
size of individual plaques has been inferred to be roughly constant in time, with a
characteristic length of 1.3 µm, indicating that disease progression consists mainly in
accumulation and aggregation of individual plaques.
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Following this analysis, Stanley et al. have built a mathematical model for the
aggregation and disaggregation of senile plaques on a discrete lattice, i.e. as a random
field [73]. This stochastic model also incorporates sudden plaque formation. The
latter is consistent with recent evidence that plaques can form rapidly, even within
1-2 days [125]. A more detailed model, incorporating inflammatory processes as well,
has been developed by Edelstein-Keshet and co-workers [134].
Shortly thereafter, a chemotactical model emphasizing the role of microglia in
the aggregation of senile plaques has been investigated, that unfortunately does not
capture the observed dynamics well [135]. The distribution of plaques and microglia,
however, seems to be in agreement with observations [136]. For a discussion of mi-
croglia in the context of mouse models, see the reviews in [137] and [138]. Imaging of
plaques has been addressed in [139], where a mathematical model for the kinetics of
PET molecular imaging probes that bind to plaques is proposed.
MR images of senile plaques can be modeled by Markov random field models (or
more generally, stochastic image models), where the values of each voxel are considered
realizations of a probabilistic process Xij , indexed by coordinates i and j in 2D. For
simplicity, these processes are assumed Markovian; to be more precise, the conditional
probability P (Xij |Xkl, (i, j) 6= (k, l)) is determined by the distribution of its direct
neighbor voxels only:
P (P (Xij |Xkl, (i, j) 6= (k, l)) := P (P (Xij |Xkl, (i, j) 6= (k, l), |i − k| ≤ 1, |j − l| ≤ 1).
Alternatively, such a process is characterized by a Gibbs distribution, i.e. a potential
energy associated with each realization (image) [140]. Medical applications of this
methodology are mainly found in image segmentation up to now, e.g., of lung tissue
or anatomical regions in brain images. In particular, a usable parametric random
field model of plaque distributions in brain tissue is still lacking. A different approach
to the analysis of plaque distributions in images is the language of fractals, where an
image is considered to consist of morphological features that are self-similar, exhibiting
the same structural properties at more than one scale. In [141] the authors have
found that cortical blood vessel structure, evaluated with fractal-based morphological
descriptors, can be correlated with AD pathology. Among other things, estimates of
correlation dimension in Alzheimer patients showed smaller values than in controls.
3.5 Cerebral amyloid angiopathy
Alzheimer’s disease is a multi-factorial disease that can be associated with cerebrovas-
cular lesions in addition to the aforementioned plaques, the formation of NFT and
brain atrophy. In fact, such lesions are often correlated with neurodegeneration. De
la Torre and Mussivand suggested in 1993 that a disturbed brain microcirculation
can cause Alzheimer’s disease [143] and further studies confirmed that the reduced
cerebral blood flow (CBF) that accompanies AD correlates well with the severity of
dementia [144, 145]. A possible cause of CBF abnormalities in AD is cerebral amy-
loid angiopathy (CAA). This particular form of vascular pathology is caused by the
deposition of β-amyloid protein in cerebral vessels [146–148].
24
































































































































































































































































































































































































































































































































































































































































































































































































































































































































Multiphoton microscopy with a contrast agent showed that plaque development
progresses seemingly linearly in Tg2576 mice [149, 150], with an average increase of
0.35% per day in vascular involvement, i.e. vessel area affected. In APPSWE/PS1
mice, CAA progresses slower with a slope of 0.17% per day [151].
Magnetic resonance angiography (MRA) can be applied to visualize vascular struc-
tures. The MRA technique differs from MRI in that the signal of stationary tissue
is suppressed, and the signal from flowing blood is made visible. MRA is commonly
applied to study flow artifacts or defects, to determine whether the vascular structure
has been compromised. As in AD neurodegeneration is commonly correlated with
CAA, MRA might provide insight into a possibly altered blood supply to specific
brain regions. Only a few MRA studies in transgenic mice have so far been reported;
in 2003 Beckmann et al. [152] studied 10 APP23 and 10 control animals at ages 6-7,
11 and 20 months, and observed flow voids in the majority of large brain arteries of
APP mice with increasing age, including severe defects such as the absence of one of
the carotid arteries. In 2004 Krucker et al. [153] used MRA to non-invasively study
the arterial vascular architecture of APP23 mice. Due to the limited spatial resolution
of MRA, the in vivo studies were complemented by analysis of the vasculature using
vascular corrosion casting. Both techniques revealed age-dependent blood flow alter-
ations and cerebrovascular abnormalities in these mice. Thal et al. [154] used MRA
to show blood flow alterations in the thalamic vessels of APP23 mice. CAA-related
capillary occlusion in the branches of the thalamoperforating arteries of APP23 mice
corresponded to the occurrence of blood flow disturbances. Similarly, CAA-related
capillary occlusion was observed in the occipital cortex of human AD subjects more
frequently than in controls.
3.6 Volumetric methods
Brain atrophy has been pointed out as a biomarker for the development of Alzheimer’s
disease in human patients with Mild Cognitive Impairment (MCI) [155–159]. Most
studies reported neurodegeneration in the structures of the mesial temporal lobe, such
as the hippocampus, parahippocampal gyrus and amygdala, as a result of Alzheimer’s
disease. Brain atrophy can be quantified and followed in time by performing volu-
metric measurements in MRI. Voxel-based morphometry is an essential step in these
types of analysis [160], and it is crucial that the necessary image registration steps
are performed correctly [41]. A review paper on this topic was recently published by
Ramani et al. [57]. Although there is overwhelming evidence on the utility of volumet-
ric biomarkers from human studies, most research in the development of transgenic
mouse models has focused on models which develop Aβ aggregation (diffuse plaques
and amyloid plaques), usually combined with an emphasis on astro- and microglio-
sis. Only in the last decade, small animal research has turned towards the study
of neurodegeneration of specific brain regions. Recently it has been found that the
progression of amyloid deposition in APP mouse strains is correlated to a decrease in
neurogenesis in the hippocampal region [161].
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Brain morphometry in transgenic mouse models of Alzheimer’s disease is challeng-
ing due to the small size of the structures of interest in the brain and the low contrast
between these structures. Although manual segmentation is still considered as the
gold standard in morphometric studies, the variability in these findings is large [162].
This problem is overcome by automated segmentation methods, which not only re-
duce the amount of time needed for delineation, but also improve the objectivity and
repeatability of the segmentation, especially when a brain atlas is used as a tem-
plate [63]. MRI enables the creation of digital atlases to describe the anatomy of
mice [163, 164] by averaging normalized MRI scans of a group of animals. This has
been of considerable interest in the analysis of various phenotypes [10, 162, 165] and
is used in the comparative analysis of both in vivo [9] and ex vivo MR images [6, 8].
An example of such an atlas is shown in section 4 in figure 4.2.
To study brain atrophy it is a prerequisite to compare images to an atlas and
several studies employ registration algorithms to automatically perform this task.
Nonlinear registration is generally superior to simple affine registration, although it
is much more sensitive to noise and image distortion. MR images of high quality are
therefore required for nonlinear registration [91]. Another way to study neuroanatom-
ical differences between mouse strains, is the statistical analysis of landmark points
after nonlinear registration, as employed by Chen et al. [35]. Falangola et al. [109]
applied nonlinear registration techniques to quantify group averages of three distinct
mouse strains and proved that nonlinear registration is able to detect small differences
of in vivo MR images. In addition to cross-sectional studies, longitudinal studies can
be performed. Verma et al. created a longitudinal map of the average brain develop-
ment in multiple C57BL/6J mice [166], the so-called spatio-temporal heterogeneity
map of brain development and maturation. Recently, Maheswaran et al. applied non
linear deformation analysis to both in vivo cross sectional as well as longitudinal
studies [167].
3.7 Texture analysis
The texture of an image is an elusive concept that can be roughly defined as its
statistical properties at different levels of scale [164]. Above we have already discussed
the characterization of plaque burden in terms of stochastic image models, which is a
particular approach. Here we discuss three more branches of texture analysis (see also
[71, 119, 168, 169]). The statistical approach is specifically targeted at discrimination
purposes. To this respect, from a given image or a ROI a number of feature descriptors
are computed. The classic example is gray-level co-occurrence matrices (GLCM) in
2D [170]. Let (i,j) be a displacement vector in 2D. For each possible pair (r,s) of
gray-level values, i.e. discretized relaxation rates for our purposes, its number of
occurrences in the image X is counted. All such co-occurrences define a symmetric
matrix: C(r, s | i, j) = |{(k, l)|Xkl = r,Xk±i,l±j = s}|. Two examples are shown in
Fig. 3.2, where for simplicity the MR parameter has been discretized at 8 levels. For
each of these matrices, distinct statistical measures can be defined. The energy of
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the matrix is the sum of its squared entries C2(r, s | i, j), and quantifies the image
inhomogeneity. The contrast is the sum of |r − s|2·C(r, s | i, j) over all pairs (r, s),
and measures local image variations.
Other commonly used feature descriptors are entropy measures, which can also
be directly estimated from images [171]. The latter has been applied to T2 images
in a cuprizone mouse model, for example [172]. With respect to Alzheimer’s disease,
Freeborough and co-workers used a total of 17 feature descriptors, selected from an
initial set of 260 descriptors, most derived from GLCMs, to classify and track the
progression of the disease in T1 images of human brains [173]. Liu and colleagues
used an initial set of 3456 descriptors to classify T1 images of humans [174]. The
cross-validated accuracy exceeded 90 percent in both cases. Kovalev and colleagues
discuss the use of discrete anisotropy measures to classify general cerebral pathologies
in 3D [175], but do not perform a statistical analysis.
Another branch of texture analysis is the signal processing approach. In its simplest
form an image is analyzed in frequency space, i.e. its discrete Fourier transform is
the basis for discrimination based on the occurrence of specific frequency components
or power changes. A more advanced method is the use of discrete Gabor or wavelet
transforms to extract localized frequency information. An example of the latter is the
classification of regions in T1-weighted images of human knees with respect to tissue
type [176].
More recently, geometric methods have been used to classify MR images. The
main idea is to consider the image as consisting of a number of smaller texture el-
ements whose distribution indicates changes in structural composition. This was
demonstrated on human x-ray mammographic images, classifying them with respect
to whether radiological findings were present or not, and this method appears suitable
to the analysis of relaxometric data as well [177]. Table 3.4 summarizes the literature
on the classification or detection of AD in human studies by texture analysis. Up
to now this approach has not been used in mouse models, and only Freeborough et
al. [173] consider a longitudinal approach (for the tracking of AD).
3.8 Discussion and conclusion
Summarizing the literature, we can conclude that tracking of relaxometric changes,
supplemented by parametric image models and the analysis of image features, is a
promising approach to the early detection of the characteristic features of Alzheimer’s
disease in mouse models. T2 relaxation times were uniformly found to be the best
discriminator, whereas T1 could not sufficiently discriminate between mutants and
their controls. Both changes in T2* and T1rho were found to correlate with aging as
well, which warrants further research efforts.
Plaque burden analysis of in vivo MRI is comparable to the relaxometric approach.
Figure 3.3 shows the age of mice in weeks for which features of AD are detected with
in vivo MRI by several plaque detection methods (light grey bars) and by relaxometric
methods (dark grey bars). Since the APP/PS1 mouse model features a more aggres-
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Table 3.4: Texture analysis applied to alzheimer’s disease on human data. AD:
Alzheimers disease, MCI: Mild cognitive complainers, C: controls.
sive progression of pathology development, the results are grouped by APP/PS1 mice
and the remaining mice (PS1, Tg2576 and further APP variants).
Direct imaging of plaque burden is very valuable in the creation and validation of
mathematical models of plague aggregation. Ultimately, it is desirable to incorporate
this knowledge into parametric image models, as this should allow for an increase of
sensitivity in the detection of AD from relaxometric images. This is further substan-
tiated by the success of texture analysis of MR images. Unfortunately, the few studies
undertaken in this regard are phenomenological, and a truly convincing solution for
the early detection of Alzheimer’s disease does not yet exist. Related to this is the
important problem at which size senile plaques are detectable under a prescribed
significance level.
As for the volumetric analysis of MRI data, research in human patients has shown
that this approach allows the prediction of the development of AD in patients al-
ready suffering from mild cognitive impairment (which does not necessarily lead to
AD). However, in small animal research this approach is still in an early phase of
development. Obviously, it is difficult to detect and quantify cognitive impairment in
animals (confer [178,179] though). The quantification of cerebral amyloid angiopathy
by MRA also appears to be promising, especially in tracking the progression of the
disease. However, this is again a mostly unexplored area. It has been demonstrated
that early detection of AD is feasible by these two approaches, but the results as yet
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Figure 3.2: Statistical texture analysis of MR images: Original image (A). Enlarged
10Ö10 subimage (B). Gray level representation with 8 levels (C). Co-occurence ma-
trix C(r, s|1, 0) of subimage for horizontal displacement (D). Co-occurence matrix
C(r, s|0, 1) for vertical displacement, which describes the statistical properties of the
subimage with regard to local variations (E).
are not as convincing as when employing relaxometric data.
In general, MR imaging is very attractive due to its non-invasiveness and its abil-
ity to produce images of high quality, and thus very suitable to study Alzheimer’s
disease in transgenic mouse models. When performing in vivo imaging on transgenic
mice environmental factors, such as the use of anesthetics, stress caused by the imag-
ing process, or even the specific mouse strain used are all confounding factors that
influence imaging results [180]. Therefore it is necessary to also study the influence
of environmental factors in transgenic mouse models of AD, especially in longitudinal
or cognitive studies, where the choice of a correct statistical model is important. If
sufficient data is available, these effects can be modeled and estimated, for example
in a GLM.
Automated analysis of MR images is a nontrivial task. The relatively large differ-
ences between scanners, the possibility of artifacts, and the large number of scanning
parameters demand standardized imaging protocols and involved methods of image
analysis. Automated analysis methods can overcome some of the problems associated
with low spatial resolution, low signal-to-noise ratio and inter-group variability, but
it seems that there is still a need for the development of new imaging protocols that
are specifically targeted at the visualization of amyloid plagues and other symptoms
of AD.
With regards to the literature, a striking general observation is that there are rel-
atively few longitudinal studies, and almost no effort to utilize temporal information
in the detection of AD. On one hand, it is not immediately obvious how to do this.
On the other hand, the main problem in discrimination tasks is the following: there
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Figure 3.3: Overview of the minimum age at which Alzheimer pathology was detected
in in vivo MRI volumes of APP/PS1 mice (A) and the remaining mouse models (B).
Dark grey denotes a relaxometric method, light grey denotes that AD pathology was




do exist significant differences between groups of diseased individuals and groups of
controls, as the above cited studies have shown. On the level of the individual, how-
ever, the (usually considerable) overlap between the two populations renders correct
classification difficult. But by following an individual through the course of time,
even if it is only a few measurements over the course of a few months, changes can be
detected that are otherwise unnoticeable. We believe that this is the key to an early
detection of AD, and expect that future studies will be conducted in this direction.
To conclude, small animal imaging will always be ahead of imaging in human
patients, as small animals can be exposed to higher field strengths and their aging
process is more rapid. This makes murine models the perfect testbed for the devel-
opment of detection and screening procedures. Also, small animals provide a way
to test and apply new treatment strategies and experimental medication. We should
not forget, however, that the ultimate goal of our research efforts is its application to
humans.
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3.A The most commonly used AD mouse models
just creating some white space
PDAPP [91]:
The first mutant amyloid precursor protein (APP) transgenic mouse model with ro-
bust plaque pathology. These mice express a human APP cDNA with the Indiana
mutation (APPV717F). Plaque pathology starts between 6-9 months in hemizygous
PDAPP mice. There is synapse loss, but cell loss and NFT pathology are not ob-
served. This model has been used widely in vaccination therapy strategies.
Tg2576 [94]:
This model expresses mutant APPSWE under control of the hamster prion promoter.
Plaque pathology is observed from approximately 9 months of age onwards. These
mice have cognitive deficits but show no cell loss or NFT pathology. Tg2576 is one
of the most widely used transgenic models.
APP23 [88,89,103]:
These mice express mutant APPSWE under control of the Thy1 promoter. Prominent
cerebrovascular amyloid and cerebral amyloid deposits are observed from 6 months
of age onwards. Some hippocampal neuronal loss in this model is associated with
amyloid plaque formation.
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TgCRND8 [95]:
Mice express multiple APP mutations (Swedish plus Indiana). Cognitive deficits
coincide here with rapid senile plaque development at approximately 3 months of
age. The cognitive deficits can be reversed by Aβ vaccination therapy.
PS1M146V and PS1M146L [90]:
These models were the first in vivo demonstration that mutant presenilin 1 (PS1)
selectively elevates Aβ42 levels. No overt plaque pathology is observed though.
PSAPP (Tg2576ÖPS1M146L, PS1-A246E+APPSWE) [87,93]:
A bigenic transgenic mouse model which showed that addition of the mutant PS1
transgene markedly accelerates amyloid pathology compared to singly transgenic mu-
tant APP mice, demonstrating that the PS1-driven elevation of Aβ42 enhances plaque
pathology.
APPDutch [92]:
Mice expressing APP with the Dutch mutation, which causes hereditary cerebral hem-
orrhage with amyloidosis in humans, develop severe congophilic amyloid angiopathy.
The addition of a mutant PS1 transgene redistributes the amyloid pathology to the
parenchyma, indicating differing roles for Aβ40 and Aβ42 in vascular and parenchy-
mal amyloid pathology.
BRI-Aβ40 and BRI-Aβ42 [96]:
These mice express individual Aβ isoforms without over-expression of APP [96]. Only
mice expressing Aβ42 develop senile plaques and CAA, whereas BRI-Aβ40 mice do
not develop plaques, suggesting that Aβ42 is essential for plaque formation.
JNPL3 [106]:
These mice express 4R0N microtubule associated protein tau (MAPT) with the P301L
mutation. This is the first transgenic mouse model with a marked tangle pathology
and cell loss, demonstrating that tau protein alone can cause cellular damage and
neuronal loss. JNPL3 mice develop motor impairments with age owing to severe
pathology and motor neuron loss in the spinal cord.
TauP301S [85]:
This line of mice expresses the shortest isoform of 4R MAPT with the P301S mutation.
Homozygous mice develop severe paraparesis at 5-6 months of age with widespread
neurofibrillary pathology in the brain and spinal cord, and neuronal loss in the spinal
cord.
TauV337M [104]:
Mice express low level synthesis of 4R MAPT with the V337M mutation (1/10 of
endogenous mouse MAPT) driven by the promoter of platelet-derived growth factor
(PDGF). The development of neurofibrillary pathology in these mice suggests the




Mice express 4R human MAPT with the R406W mutation under control of the
CAMKII promoter. These mice develop MAPT inclusions in the forebrain from 18
months of age onward and have impaired associative memory.
rTg4510 [101,102]:
Mice have inducible MAPT using the TET-off system. Abnormal MAPT pathology
occurs from one month of age on. These mice show progressive NFT pathology and
severe cell loss. Cognitive deficits are evident from 2.5 months of age onwards.
Htau [86]:
These transgenic mice express human genomic MAPT only (mouse MAPT knocked-
out). Htau mice accumulate hyperphosphorylated tau from 6 months on and develop
Thio-S-positive NFT by the time they are 15 months old.
TAPP (Tg2576ÖJNPL3) [116]:
mice have increased MAPT forebrain pathology when compared to JNPL3 mice,
suggesting mutant APP and/or Aβ can affect downstream MAPT pathology.
3ÖTgAD [98,99]:
This is a triple transgenic model expressing mutant APPSWE and MAPTP301L on a
PS1M146V ’knock-in’ background (PS1-KI). This line develops plaques from 6 months
on, and MAPT pathology from the time they are 12 months old, strengthening the
hypothesis that neurofibrillary pathology can be directly influenced by APP or Aβ
APP717I [97]:
Mice express human APP cDNA with the London mutation (APPV717I). This strain
displays decreased exploration, increased neophobicity and increased male aggressive-
ness. Pathological features include amyloid plaques and cerebrovascular angiopathy
with an onset around 10-12 months, and cholinergic fiber distortion.
APPV717IÖADAM10-dn [100]:
Double transgenic mice expressing both APPV717I and a proteinase of the ADAM
(a disintegrin and metalloproteinase) family. Expression of ADAM10-dn leads to
an enhancement of the number and size of amyloid plaques in the brains of these
double-transgenic mice. However, compared to APPV717I mice, they exhibit improved
performance in the Morris water maze test.
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Chapter 4
abstract: Segmentation of MRI data is required for many appli-
cations, such as the comparison of different structures or time-
points, and for annotation purposes. Currently, the gold stan-
dard for automated image segmentation is nonlinear atlas-based
segmentation. However, these methods are either not sufficient
or highly time consuming for mouse brains. This is due to the
low signal-to-noise ratio and low contrast between structures com-
pared to other applications. We present a novel generic approach
to reduce processing time for segmentation of various structures
of mouse brains, in vivo as well as ex vivo. The segmentation
consists of a rough affine registration to a template followed by
a clustering approach to refine the rough segmentation near the
edges. Compared to manual segmentations, the presented segmen-
tation method has an average kappa index of 0.7 for 7 out of 12
structures in in vivo MRI and 11 out of 12 structures in ex vivo
MRI. Furthermore, we found that these results were equal to the
performance of a nonlinear segmentation method, but had the ad-
vantage of being 8 times faster. The presented automatic segmen-
tation method is quick, intuitive and can be used for annotation
and volume quantification of structures.
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4.1 Introduction
The versatility of MRI techniques makes animal MRI suitable for the identification
of new disease biomarkers and evaluation of novel diagnostic or therapeutic agents,
similar to clinical MRI [61, 181]. Studying neurological disorders in mouse models
often requires segmentation to perform either phenotyping or morphometry. Although
sophisticated automated methods assist in the analysis of the full mouse brain [28,35],
segmentation or delineation of the structures of interest (SOI) is necessary to evaluate
which structure is involved and exactly how that structure changes.
Manual segmentations are, although tedious, generally considered as the golden
standard for brain annotations. Automation of the segmentation process has some ad-
vantages above manual delineations, such as repeatability and standardization. Since
animal MR scanners are still in the developmental phase, automated segmentation in
mouse MR images is still very challenging, in contrast to the automated segmentation
of human brain MR images [182]. Most algorithms developed for the human brain
segmentation are not directly applicable to mouse brain images, as Tohka et al. [183]
recently presented. These segmentation problems in mouse brain MRI are mostly
due to artifacts caused by the MRI scanner, deformations caused by the excision of
the brain in the case of ex vivo imaging and, most importantly, less contrast between
brain structures and a lower signal-to noise ratio compared to human MRI.
Segmentation of mouse brain MRI for experimental studies is generally performed
by nonlinear registration of an annotated atlas to a subject, for which the segmenta-
tion is manually refined afterwards [6,8,9,38,165]. In these studies, no segmentation
performance is reported. A completely automated segmentation method based on
nonlinear registration was presented by Rohling et al., which reached a segmenta-
tion accuracy of 90% overlap with manual contours in bee brain MRI [184]. The
method consists of the nonlinear registration to several atlases which are combined
by an Expectation-Maximization classification method. The success rate of this
method is very dependent on the amount of atlases available. Another promising
fully automated segmentation method is based on probabilistic intensity information
or intensity patterns of various ex vivo imaging protocols, which were known before-
hand [162,185,186]. With this approach the automated segmentation had on average
90% overlap with manually drawn contours. It’s advantage is that no computational
expensive registration methods are required, although the usage of various imaging
protocols might be time consuming as well.
In this paper, a new, fast, and automatic segmentation method is presented that
produces segmented images of in vivo and ex vivo mouse brains based on a single atlas,
imaged by a single imaging protocol. We first applied a fast affine atlas registration to
a template to obtain a rough initial segmentation that was then refined by a clustering
algorithm. As already stated by Tohka et al. [183] regular clustering algorithms,
such as fuzzy k-Means Clustering [187] and Markov random field models [188] fail to
segment the volume properly, mainly because there is lack of contrast between the
structures. Therefore, a more specialized clustering algorithm is required, which we
present in this study. The presented clustering algorithm combines intensity values,
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the class labels of the neighboring voxels, and edge information. This information is
given to the clustering algorithm by means of a template.
The algorithm is tested on in vivo and ex vivo mouse brain MRI volumes. For both
volumes different structures are segmented based on the visibility and contrast of the
structures in the volumes. Furthermore, the performance of the algorithm is validated
by comparison to manually drawn expert contours. The in vivo MRI segmentations
are also compared to automated segmentations obtained by a nonlinear segmentation
method. For this approach, the MRI volume is nonlinearly registered to the atlas by
the Demons registration method [189].
4.2 Materials and methods
4.2.1 Experimental setup
C57Bl/6J mice (n = 5) were first imaged by MR in vivo on a Bruker 9.4 Tesla scan-
ner using a T2-weighted multi-slice spin echo sequence with TR/TE=6000/35 ms (4
averages). The in vivo volume had a matrix size of 256Ö256, with 40 slices, result-
ing in a resolution of 97.6Ö97.6Ö200 µm per voxel. The total scan time was 102
minutes. Afterwards, mice were sacrificed and the brain their brains were the skull
and perfusion-fixed with 4% phosphate-buffered paraformaldehyde (PFA). Prior to ex
vivo MR imaging, brains were incubated for 8 hours in 4% PFA containing 12.5 mM
gadolinium-tetraazacyclododecanetetraacetic acid (Gd-DOTA , Dotarem, Guerbet,
Roissy, France). Ex vivo imaging was performed using a T1-weighted 3D-gradient
echo protocol, with TR/TE=17/7.6 ms and flip angle 25 degrees. The total scan
time was 10 hours. The ex vivo volume had a matrix size of 256Ö256Ö256 and an
isotropic resolution of 78.1 µm per voxel. Figure 4.1 displays the pipeline of the pre-
sented segmentation algorithm with its two main steps: the registration to an atlas
and the clustering. Also, the required input for the algorithm is displayed. In the fol-
lowing, the various brain structures of interest are denoted as classes. The automated
segmentation for each image took on a single Pentium-IV 3.4 GHz processor approx-
imately 30 minutes for the ex vivo volume and 15 minutes for the in vivovolume.
The difference in calculation time between ex vivo and in vivo volumes is due to the
differences in number of voxels.
4.2.2 Template creation
In atlas-based segmentation, or model-guided segmentation, a new MRI volume can
be segmented if it is registered to an atlas. The atlas contains all prior information
on the average volume and spatial organization, which is useful to avoid biologically
impossible solutions. The best representative atlas for image segmentation and nor-
malization is an unbiased atlas, which means an atlas that is constructed by averaging
scans of multiple subjects in an independent coordinate system and is not dependent
on inter-subject changes [5]. If insufficient subjects are available for the creation of
an unbiased atlas, an approximation can be made as presented by Thompson and
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Toga [163], who mapped an unknown brain to a database of normal brains to acquire
an accurate segmentation.
In this study, a limited number of subjects were available which excluded the pos-
sibility to create an average unbiased atlas. So, we had to work with a template; a
single segmented volume that was selected from the in vivo and ex vivo images from
the dataset. Although an unbiased atlas is desirable, a template would suffice for this
purpose. The clustering algorithm is applied after the affine registration, adjusting
the initial segmentation until a perfect individual segmentation is reached. Due to
the differences in intensity values, contrast and noise between in vivo and ex vivo
MR images, we used both in vivo and ex vivo images of the template. Furthermore,
the number of manually segmented structures was also dependent on the visibility of
those structures. For the ex vivo atlas, 15 structures were segmented: The cortex,
midbrain-hindbrain, cerebellum, olfactory areas, hippocampal formation, caudoputa-
men, thalamus, corpus callosum, hypothalamus, fornix system, corticospinal tract,
substantia nigra, ventricles, anterior commissure - olfactory limb, and the anterior
commissure - temporal limb. For the in vivo atlas 12 structures were segmented:
The cortex, midbrain-hindbrain, cerebellum, olfactory areas, hippocampal formation,
caudoputamen, corpus callosum, fornix system, substantia nigra, ventricles, anterior
commissure - olfactory limb, and the anterior commissure - temporal limb. A coronal,
saggital and transversal view of the atlas is given in figure 4.2.
4.2.3 Registration
Each volume in the dataset is affine registered to a manual segmented template which
provides an initial segmentation. Since the registration is an intermediate step in
the segmentation algorithm, a fast and rough registration of the template to the new
volume is sufficient. For this purpose, we used a registration algorithm composed of
an affine transform with mutual information as image metric that was optimized by
a regular step gradient optimizer [190, 191] as implemented in National Library of
Medicine Insight Segmentation and Registration Toolkit (itk) [192]. When the regis-
tration has finished, the segmentation of the atlas is affine transformed and mapped
on the new MRI volume as an initial segmentation. In addition to acquiring an initial
segmentation, the atlas was also used to derive prior information on the intensity
distribution for each class as input for the clustering algorithm. Furthermore, the
initial segmentation is used to remove the skull and surrounding tissue of the in vivo
MRI volume, so the clustering algorithm will not be distracted by those.
4.2.4 Edge-based clustering
After the atlas-based registration is completed, the clustering algorithm is applied.
This clustering is necessary, since the affine registration results in an initial segmen-
tation that only accounts for global differences between the new volume and the atlas
image. The clustering corrects the segmentation for local changes caused by inter-
subject variation and deformations in the ex vivo mouse brain caused by the physical
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Figure 4.1: The segmentation pipeline for the mouse brain segmentation algorithm.
The Atlas volume is first registered to the new MRI volume, resulting in an initial
segmentation. Furthermore, the intensity distributions per class are derived from the
atlas and the edge information from the new MRI volume is extracted. The clustering
algorithm is performed in the second step for a final segmentation; therefore it uses
the class statistics, initial segmentation and edge information as input.
excision and preparation of the brain.
It is assumed that in an MR image, each voxel x has a probability p to be a part of a
certain brain structure (class c). The presented clustering algorithm uses information
on the intensity distribution and information retrieved from the N neighbors of x
to evaluate for each class c and assigns x to the class with the highest probability.
This process is iterated until it converges to a stable solution. The convergence level
is defined as the minimum percentage of voxels changing label in a single iteration.
This predefined percentage of voxels has to be set by the user. The algorithm usually
finishes between the 5 and 10 iterations, dependent on the convergence threshold set
by the user and the quality of the initial segmentation. The latter is provided by the
first step of the algorithm, the affine registration, as described in the section above.
The presented algorithm needs three inputs, as can be seen in figure 4.1; (a) an
initial segmentation, as given by the global atlas-based registration; (b) the intensity
distributions per class as derived from the atlas, and (c) the edge information of the
new MRI volume. As can be seen in formula 4.1 the clustering is separated in two
main components; the first one, Pintensity, is based on the intensity distribution of the
various classes and second part (Pneighborhood(c|x, n ∈ N)) is based on information
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retrieved from the neighborhood of voxel x. The knowledge on the intensity distri-
butions is derived from the atlas. The initial segmentation and the edge information
are used to calculate the neighborhood influence.
p(c|x, n ∈ N) = (1− α)Pintensity(c|x) + αPneighborhood(c|x, n ∈ N) (4.1)
with 0 ≤ α ≤ 1. The weight α is used to tune the algorithm for the various contrast-
to-noise ratios and signal-to-noise ratios, depending on the imaging protocols of the
MRI scanner. If the image volume has very high contrast, the emphasis may lie
on the probability from the intensity, so α should be smaller than 0.5. If the data
is very noisy, the probability calculated from the intensity is less reliable. In this
case, α should be put higher than 0.5 since the edges can still be found correctly by
using an anisotropic smoothing filter. The first part of the clustering algorithm, the
Pintensity(c|x), is used to incorporate the intensity distribution of the various classes.
It measures the relative distance of each voxel x of the complete volume X to the
class mean intensity of each class c (x̄c), where the shortest distance has the highest





The second part of the probability function, the Pneighborhood(c|x, n ∈ N), models the
dependency on the neighboring voxels. The influence of the neighbors is weighted by
the edge information obtained from the original image, since the initial segmentation
is usually erroneous near the edges, especially when the segmentation is found by
global atlas registration. Therefore, the neighbors that are located inside a structure
have more influence than the neighbors located on or close to a (strong) edge. The
edges are found by a standard Sobel filter S(x) and, afterwards, the intensities of the
image are scaled to range from 0 to 1. For this algorithm, we use a second order
neighborhood, which means all voxels located next to x in a horizontal, vertical, and
diagonal direction are included in N , thus resulting in a neighborhood of N = 33 = 27
voxels, including x itself. The nc in formula 4.3 symbolizes that for each class c,
neighbors can only contribute if they are also classified to c.







For validation purposes, all brains were manually segmented in concordance of two
experts, who used the LONI mouse brain atlas [10] as guidance. This is a standard-
ized mouse brain atlas from the Laboratory of Neuro Imaging at the University of
California. The structures which were selected for manual and automated segmenta-
tion, were selected by the experts based on their visibility in the MR images. The
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results of the automated segmentation method were validated by comparing them to
the manual segmentations of experts by means of the kappa index κ, as given in eq.
(4.4). The kappa index is a measure that represents a ratio of the amount of overlap
to the total number of voxels of an automatically segmented brain structure Va and







This measure is robust to changes in volume size and therefore very suitable to com-
pare the automated and manual segmentation. A κ of 1.0 indicates total overlap of
two volumes, where a κ of 0.0 shows no overlap at all. In an inter-observer study [162]
it was shown that an automated segmentation method was performed equally as well
as human observers if the kappa indices between 0.7 and 1.0 can be achieved. An
overall validation score of the algorithm is obtained by averaging the kappa indices
per structure for all volumes in the dataset.
4.3 Results
4.3.1 Automated segmentation results
For the segmentation of the ex vivo images, the algorithm used on average 6 iterations
to reach the threshold when less than 0.5% of the voxels changed label, while for the
in vivo segmentation only 3 iterations were needed for convergence to a 5% threshold.
The different settings for the convergence threshold is a consequence of the different
voxel sizes of the mouse brain in the ex vivo and in vivo images; which is respectively
127,655 voxels and 833,800 voxels. The automated segmentation for each image took
on a single Pentium-IV 3.4 GHz processor approximately 20 minutes for the ex vivo
volume and 15 minutes for the in vivo volume. The difference in calculation time is
due to the differences in number of voxels.
The average kappa indices are calculated for all automatically segmented struc-
tures and displayed in Table 4.1. Also given are the volumes of the segmented struc-
tures in voxels. As stated in the previous section, an automatically segmented struc-
ture with κ larger than 0.7 can be assumed to be segmented with reasonable accuracy.
If we consider the in vivo automated segmentation, the algorithm reached a satisfy-
ing result for 7 of the 12 structures with an average κ of 0.7. In the case of the ex
vivo segmentations, 12 out of 15 structures are correctly segmented with an average
κ of 0.85. These results imply that the automated segmentation method for ex vivo
MR images is comparable to manual segmentations, as Ali et al. has shown with an
intra-observer study which reached an average κ of 0.85 [162]. The automated seg-
mentation method from Sharief et al. [186] outperforms the presented method with
an overall kappa index of 0.95. However, their method is only applicable to ex vivo
MRI, since they use various imaging protocols whereas the presented method is also
applicable on in vivo MRI.
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Figure 4.2: The MRI atlas used for in vivo(E,G) and ex vivo(F,H) MR images with
their manual segmentations (A,B,C, and D) and corresponding names and abbrevi-
ations. For a better understanding, the abbreviations for the brain structures are in
upper case where the abbreviations for brain tracts are in lower case.
Figure 4.3: A visual comparison between the manual (M) and automated (A) seg-
mentation for in vivo MRI (left) and ex vivo MRI volumes (richt). The colour-coding
of the various classes correspond to the legend as given in figure 4.2.
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If the number of voxels are compared to the final κ, it can be seen that the
performance of the algorithm decreases with the size of the structure to be segmented.
This is especially true for the brain tracts included in the segmentation algorithm: the
corpus callosum, corticospinal tract, and the anterior commissures. To illustrate the
differences in segmentation for the in vivo and ex vivo images, an automatically and
manually segmented slice are displayed in figure 4.3. Most structures have an overall
better segmentation result in the ex vivo images, due to a better contrast-to-noise
ratio and a higher resolution. The effect of these parameters is clearly visible if one
considers e.g. the corpus callosum. However, some brain structures suffer from major
deformations caused by the excision of the brain, impairing an accurate automatic
segmentation of ex vivo. Examples are the olfactory areas, which are easily damaged
during excision, or the ventricles which often collapse post mortem and therefore
have a smaller volume leading to worse segmentation results for the ex vivo images.
In figure 4.3, one can clearly see differences in proportion for the ventricles in in vivo
and ex vivo images.
In figure 4.4 we presented the kappa indices of the ex vivo segmentations after
the first step of the algorithm (the affine atlas-based registration) and its second step
(the clustering algorithm). This figure shows that only for the three brain tracts, the
fornix system and anterior commissures, a decrease in κ is obtained after the cluster-
ing is performed. For the anterior commissures, this decrease is also found significant.
The κ increases for all other structures and although this increase seems unimportant
and small in the figure, we found a significant increase in κ for all structures except
the cortex, midbrain-hindbrain, and caudate putamen. For these three structures
the initial segmentation is already quite accurate, leading to minor adjustments by
the clustering algorithm. These minor corrections may not be a significant improve-
ment, but are still important since these small changes are actually corrections for
the inter-subject variations. The structures, for which a significant improvement of
segmentation was found, are the structures which have a less accurate initial seg-
mentation compared to the cortex, midbrain-hindbrain and caudate putamen and
therefore need more correction by the clustering algorithm.
4.3.2 Nonlinear atlas-based segmentation
To compare the performance of the proposed algorithm to atlas-based nonlinear seg-
mentation, nonlinear registration of the annotated template to the subjects was per-
formed by means of the symmetric Demons algorithm as implemented in itk [192].
This nonlinear registration method is based on a thermodynamic concept of diffu-
sion [189].
The same procedure was followed for the presented segmentation method; the
same in vivo image was used as atlas, as shown in figure 4.2, while the segmentation
algorithm was evaluated on the other in vivo images. Before applying the Demons
algorithm, the in vivo images were affine registered by the same algorithm as used
for the atlas-based registration of the newly presented method. The average kappa
indices are retrieved by comparing the results from the automated segmentation to
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the manual segmentation of the in vivo mouse brain volumes. The results of the
nonlinear registration to the atlas can be found in figure 4.5. As can be seen in the
figure, the results of the algorithm are comparable with the results of the demons
algorithm, where the clustering method reached convergence in 10 minutes and the
Demons algorithm reached convergence in 2 hours on the same computer.
Figure 4.4: The increase in κ between the two steps of the presented algorithm for the
ex vivo segmentation results. The light grey bar denotes the average κ after the affine
atlas-based registration step, whereas the dark grey bar displays the average κ after
the clustering step. Furthermore, the standard deviations are given for each bar to
indicate the robustness of the algorithm. The abbreviations of the various structures
are explained in figure 4.2
Figure 4.5: The average kappa indices of the Demons algorithm (light grey bars)
compared to the average κ of the presented method (dark grey bars) for the in vivo
mouse brain segmentation. Furthermore, the standard deviations are given for each
bar to indicate the robustness of the algorithm. The abbreviations of the various
structures are explained in figure 4.2
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4.4 Discussion
As described in the results, the algorithm was found to segment the larger brain
structures, e.g. cortex or cerebellum correctly. For these structures, the algorithm
performs equally to the kappa indices from literature [162]. The results are also
comparable for one of the most challenging structures in the ex vivo brain, the corpus
callosum. This structure is challenging to segment because it is assumed to be large
with an average of 37,990 voxels (18.11 mm3), but its flat and thin shape resembles
more of a small structure. The algorithm has a high segmentation performance on
structures which are affected by noise or deformations and have low contrast. This
performance can be obtained by the usage of neighborhood voxels in combination
with the edge information of the unknown brain image. A drawback of this method
is, however, that the algorithm has less accurate segmentation on structures having
a width of the image resolution. This can be seen in figure 4.4, where the three brain
tracts, the fornix system and anterior commissures show a decrease in kappa index
after the clustering is performed. This is due to (a) the usage of a single image as
atlas for the segmentation. Small inter-subject variations result in a misregistration
for the smaller structures in the brain, in such a way that there is no overlap and
thus no seed point for the algorithm to segment this structure, (b) the partial volume
effects that reduce the contrast between the neighboring structures. The voxels on the
boundary of a structure have an intensity that is similar to its neighboring structure
and have a higher chance at incorrectly classification.
By comparing the in vivo to ex vivo segmentations, the algorithm returns a better
segmentation for the ex vivo images, except for the olfactory areas and ventricles.
The superior segmentation of the ex vivo segmentation can be explained by the lower
resolution of the in vivo volume, resulting in more structures for which their widths
are about the resolution of the image. As mentioned above, the algorithm encounters
more difficulties when segmenting structures with a limited number of voxels. The
superior segmentation of the olfactory areas and ventricles in the in vivo volumes
can be explained by the local deformations occurring during the extraction of the
brain from the skull. The olfactory areas are very loosely attached to the brain
and in most cases were damaged or completely removed in the procedure, while the
ventricles collapse if the brain is fixed. The latter is shown by table 4.1, where the
volumes in mm3 are given for all structures. Although the segmentation algorithm
can compensate for of these changes to some level, these deformations still cause some
errors. The boundaries of some brain structures, e.g. the transition of the midbrain-
hindbrain to the thalamus, are difficult to determine due to little contrast differences
in the image between the structures. For these structures, the manual segmentation
is also subjective and differs for each mouse brain. In this study, two experts were
used to validate the manual segmentation and obtain a more objective segmentation.
However, more information on the user variability is needed for these structures before
some conclusions can be drawn on the quality of the automated segmentation of these
structures.
The automated segmentation of the structures with poor edge information is very
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dependent on the atlas, since the clustering is guided by the prior information given
by the manual segmentation of the atlas. For these structures, the main differences
between the automated segmentation and the manual segmentation are the differ-
ences in the transformed expert segmentation of the atlas mapped on the image on
one hand and the manual segmentation of the new image as validation on the other
hand. This raises the need for a publically available average atlas that also includes
inter-variability and intra-variability information for these structures, as already de-
veloped for human brains [193]. We found that the presented segmentation method
has similar performance as the nonlinear segmentation method. If compared to the
expert segmentations, the performance of the presented method is more consistent.
Manual segmentation is still considered the most reliable method although the intra-
observer variation is on average higher than in automated algorithms. This is due to
different interpretations of the various structures, as well as tiredness and weariness of
the observer. Therefore, an automated segmentation algorithm not only reduces the
amount of time needed to segment, but also improves the objectivity of the segmen-
tation. Especially, when there is good contrast between structures, the automated
segmentation algorithm will return a good and objective segmentation which is also
repeatable.
The algorithm has one limitation caused by the extraction of prior knowledge
on intensities and edges from the atlas. If the imaging protocols differ, incorrect
intensity distributions per brain structure are derived from the atlas and do not
represent the intensity distribution per structure. Since these distributions are used
to guide the clustering, the clustering will result in an incorrect segmentation. So,
it is required that the atlas is either acquired with the same imaging protocol as the
image dataset, or has to be preprocessed by some intensity transform to map the
intensities on the protocol of the new image dataset. In practice, the last method
is the most likely choice, although errors made in the intensity mapping will induce
errors in the segmentation of the volumes. If an atlas - or example segmentation -
can be obtained, it is more likely that a better segmentation result is reached. Future
work will also include a study on the segmentation of other types of MRI. We will
investigate the performance of this segmentation method for other images, since no
specific brain tissue information is used and consequently all the posterior information
for the clustering is derived directly from the atlas. In summary, the presented method
is a quick and promising segmentation method for mouse brain images, especially
when major deformations of the tissue are absent. The smaller, local deformations in
the brain tissue are corrected by the adapted clustering algorithm as a complement of
the linear registration. This collaboration of both segmentation algorithms result in
a quick and accurate segmentation method for in vivo and ex vivo mouse brain MRI,
despite its low signal-to-noise ratio and artifacts. Finally, since no prior information
has been used in this segmentation algorithm, this algorithm is highly generic and
can be applied on various images without any difficulties.
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4.5 Conclusion
The main objective of this study was to find a new, fast, and fully automatic segmen-
tation method that produces segmented images of in vivo and ex vivo mouse brains
based on a single atlas, imaged by a single imaging protocol. The presented method
consists of an affine atlas-based registration combined with an edge refining clustering
algorithm, where the clustering is supplemented by edge information and statistical
information derived from the anatomical atlas. It is shown that the addition of the
clustering algorithm improves the segmentation and is able to compensate for some
nonlinear deformations in the ex vivo mouse brain. Where fully automated and highly
accurate segmentation methods for in vivo and ex vivo mouse brains are extremely
time consuming, e.g. by nonlinear registration, the presented method is quick and
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Chapter 5
abstract: The Rayleigh test is a popular one-sample test of
randomness for directional data on the unit circle. Based on
the Rayleigh test, Moore developed a nonparametric test for two-
dimensional vector data that takes vector lengths into account as
well, which is generalized to arbitrary dimensions. In the im-
portant case of three-dimensional vector data the asymptotic dis-
tribution can be given in closed form as a finite combinatorial
sum. This reduces the computational effort considerably. In par-
ticular, when analyzing deformation fields arising in nonlinear
brain registration, the generalized Moore-Rayleigh test offers an
efficient alternative to conventional permutation testing for the
initial screening of voxels. Simulation results for a few multivari-
ate distributions are given and the test is applied to brain scans
of hydrocephalic transgenic mice. Compared with the permutation
version of Hotelling’s T 2 test its increased power allows for im-
proved localization of brain regions with significant deformations.
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5.1 Introduction
Consider the following illustrating example. In the deformation-based morphome-
try, individual brain volumes are mapped to a reference brain image by a nonlinear
transformation to assess inter- or intra-variability of the brain structures [6]. The non-
linear image registration results in a three-dimensional vector field of displacement
vectors. The significance of local deformations between groups of subjects, usually a
treatment and a control group, can be tested by either considering the Jacobian of
the deformation field, or testing the displacement vectors directly [194]. In the latter
case, if one assumes that variations between subjects are given by a Gaussian random
field, Hotelling’s T 2 statistic can be used to test for significant differences between
groups [195]. Its value is the squared sample Mahalanobis distance, estimated from
the pooled covariance matrix, and the test assumes normality of the population of
deformation vectors and equal covariances for the two groups. If these assumptions
are not met, the T 2 test is known to fail gracefully, i.e. it will still be approximately
conservative and the loss in power for the alternative will not be too dramatic for
moderate violations of the assumptions. However, it is preferable to analyze deforma-
tion fields nonparametrically. Permutation tests, with their minimal assumptions, are
the usual method of choice for this two-sample problem [35,196]. However, they also
rely on a test statistic that is evaluated for each labelling (“permutation”), and the
null hypothesis is that this statistic is distributed symmetrically around zero. The
usual choice for the statistic is again Hotelling’s T 2, so permutation tests are not
nonparametric, but rather result in adjusted significance probabilities [197].
For example, as shown in [198], the adjusted one-dimensional version of the T 2
test, i.e. the permutation version of the classic t-test, is the uniformly most powerful
test for the Gaussian alternatives with fixed variance, but fails to be uniformly most
powerful against other alternatives. A more serious practical problem is that, even
for small sample sizes, the number of permutations to consider for an exact test is
prohibitively large. Especially so, if the number of voxels, i.e. the number of tests, is
on the order of hundreds of thousands, as is common in neuroimaging applications.
Therefore, in current analyses one often limits the data to only 10,000 or less random
relabelings per voxel, at the expense of increasing the simulation error. Moreover,
correcting for multiple comparisons imposes severe lower bounds on the numbers of
relabelings needed per voxel for testing at realistic significance levels, i.e. on the
sample size and simulation time. Particularly for small sample sizes that occur in
prospective studies in mice, permutation tests cannot resolve low enough significance
probabilities to allow for strong control of the family-wise error. Even the modern,
liberal approach of limiting the False Discovery Rate [47, 50] does often not lead to
useful results in these datasets [199].
In this paper we describe a new nonparametric statistical test that allows to effi-
ciently perform a large number of such tests on vector data. The two-sample version
of the test is not provably conservative, but its advantage is that it can be used for the
initial screening of voxels. It is sensitive enough to work even under the conservative
Bonferroni correction. Voxels where the null hypothesis is rejected can then be ana-
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lyzed further by this test under the permutation distribution of the data; alternatively
a different test statistic can be employed. This problem of testing one or more groups
of vectors for distributional differences does not only arise in neuroimaging, but also
in a number of other disciplines and diverse contexts, e.g. in geostatistics, human
movement sciences, astronomy and biology. In the two-dimensional case, a natural
nonparametric test for such problems has been given by [200], which we describe next.
After generalizing this test to arbitrary dimensions, in Section 5.2.2 we focus on the
three-dimensional case, being the most important one for applications.
5.2 The Moore-Rayleigh test
Let X = (X1, . . . , XN ) be a finite sample of real k-vector-valued random variables
Xi = (Xi,1, . . . , Xi,k). If we assume that the Xi are independently drawn from a
common absolutely continuous probability distribution with density f : Rk → [0,∞),
then the null hypothesis is:
H0 : The probability density f is spherically symmetric.
Consequently, this implies that the density f is spherically decomposable. It fac-
tors into the product of a radial density pr : [0,∞) → [0,∞) and the uniform dis-
tribution on each hypersphere rSk−1 = {x ∈ Rk | ||x|| = r}, such that f(x) =
pr(||x||)/vol(||x||Sk−1). We can then write Xi = RiUi, where Ri ∼ pr and Ui is
distributed uniformly on the k-dimensional unit sphere Sk−1. The latter distribution
can be realized as the projection of a k-dimensional diagonal Gaussian distribution
with equal variance in each dimension. The sum
∑N
i=1Xi, where the Xi are indepen-
dently distributed according to a common, spherically symmetric distribution, is easy
to interpret. It corresponds to a Rayleigh random flight [201] with N steps, whose
lengths are distributed according to pr. Scaling the vector-valued random variables







where X(i) denotes the i-th largest vector in the sample (with ties being arbitrarily
resolved), is independent of pr; consequently, a test based on SN is nonparametric.





A large value of R∗N for a given sample X from an unknown distribution (not nec-
essarily absolutely continuous) indicates a deviation from spherical symmetry. This
test was introduced by [200], who treated the two-dimensional case numerically, and
has been used in neuroscience [202–204], human movement science [205] and avian
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biology [206–209].
In contrast to the Rayleigh test of uniformity [210], where the Xi are constrained
to lie on (alternatively, are projected onto) the unit sphere, in the Moore-Rayleigh
test also the vector length influences the test statistic. This follows the observation
of [211], that differences in scale between two distributions will be mostly evident in
their (radial) tails, i.e. when moving away from the mean. The interpretation of R∗N
is not so easy as in the Rayleigh test, however, where the test statistic is a measure






, (j = 1, . . . , k). (5.3)
A direct calculation shows that under the null hypothesis the variance of X(i),j/||X(i)||
is 1/k, and that
σ2 = var(SN,j) = N(N + 1)(2N + 1)/(6k). (5.4)
As E(SN,j)
3 = 0 and σ2 < ∞, the Lyapunov version of the Central Limit Theorem
implies that the random variables SN,j approach Gaussian N (0, σ2) distributions
for large sample sizes N . Although the random variables ||SN,j || are obviously not
independent, by the same argument as in [212] the corresponding distribution of
||SN ||2/σ2 asymptotically approaches a χ2k distribution. Let αN = N3/2. The exact
null distribution of RN = αNR
∗
N in k dimensions, k ≥ 2, is given by

























where Jl denotes the Bessel function of order l; see [213].
5.2.1 The one-dimensional case
In one dimension, the Moore–Rayleigh statistic for the null hypothesis corresponds




γii, where γi = ±1 with equal probability. (5.6)
Proposition 1. The probability mass function pr (SN = r)
def
= p(r,N)/2N is given
by the recurrence
p(r,N) = p(r − n,N − 1) + p(r + n,N − 1) (5.7)
with initial condition p(0, 0) = 1 and p(r, 0) = 0 for r 6= 0.
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where the sum runs over all step sizes i ∈ {1, . . . , N} that have positive sign γi, shows
that the numbers p(r,N) have a well-known combinatorial interpretation.
Proposition 2. The numbers p(r,N) count the number of partitions of 12 (r+
1
2N(N+
1)) with distinct parts less or equal to N .
As before, denote the length of the resultant by RN = ||SN ||. Its probability
function pr(RN = r) is given by
pr(RN = r) =

p(r,N)/2N−1 if r > 0,
p(0, N)/2N if r = 0,
0 otherwise.
(5.9)









2N(N + 1)) with distinct terms less or equal to N , i.e.
εr,N
def
= E(εN | SN = r). (5.11)
Anticipating the two-sample Moore-Rayleigh test discussed in Section 5.3, we note
the following:
Remark 1 (Relation to the Wilcoxon signed-rank test). In the Wilcoxon signed-rank
test for two paired samples X and Y of equal size |X| = |Y | = N , the null hypothesis is
that the paired differences Zi = Yi−Xi are distributed (independently and identically)
symmetrically around zero [214]. The test statistic is the sum W+ =
∑N
i=1 iI(Zi > 0),
where I(·) is an indicator function. Under the null hypothesis we have that pr(Zi >
0) = pr(Zi < 0) =
1
2 . Assuming that pr(Xi = Yi) = 0, which is fulfilled with
probability 1 for continuous distributions, we can then identify I(Zi > 0)− I(Zi < 0)
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Therefore, testing for symmetry of the Zi under the one-dimensional Moore-Rayleigh
test is equivalent to the signed-rank Wilcoxon two-sample test of X and Y , with
pr(W+ = r) = pr(SN = 2r −
1
2
N(N + 1), N).
This approach easily generalizes to more than one dimension.
Remark 2 (Testing for radial dependence). Assume the density f decomposes spher-
ically, such that Xi = RiUi, with Ri ∼ pr and Ui ∼ u, where pr(r) = pr(|Xi| = r)
and u(x) = pr(Xi/|Xi| = x). In one dimension, u can only attain the values
{−1,+1} and u(∓1) = pr(Xi ≶ 0). If the mean of f is zero, i.e. E(Xi) = 0,
then pr(Xi > 0) = pr(Xi < 0) = 1/2, and this implies that f is (spherically) sym-
metric. The Moore-Rayleigh test, under the assumption that Xi = RiUi, therefore
tests the null hypothesis that E(Xi) = 0. On the other hand, assume that E(Xi) = 0.
If the Moore-Rayleigh test finds a significant departure from uniformity, then this
leads to the rejection of the hypothesis that the density f decomposes in such way,
i.e. to accept the alternative that the common distribution of the random variables
Xi is conditional on the length |Xi|. In practice, centering X = (X1, . . . , XN ) by the
sample mean, the Moore-Rayleigh test could be used to detect such radial dependence.
However, its power would be quite limited and it seems likely that directly testing for
differences in the two tails {Xi > x} and {Xi < −x} will be more powerful.
5.2.2 The three-dimensional case
Taking derivatives, the distribution function of RN = αNR
∗
N , given in Eq. (5.5),
reduces to the density













in the three-dimensional case (k = 3). This formula can alternatively be derived
by using characteristic functions (see Eq. 16 in [201]). The oscillating integral in
Eq. (5.12) can be evaluated by numerical quadrature, but it is difficult to calculate
its tail accurately. Another approach to evaluate this integral is based on a finite
series representation, following an idea originally due to G. Pólya. Let Nmax =
N(N + 1)/2. If we expand sin(nt) = (ent − e−nt)/2i and integrate the oscillating
integral in Eq. (5.12) by parts N−2 times as in [215], a simple but tedious calculation
(which we omit) results in the following representation:
Theorem 1. The probability density of R∗N under the null hypothesis can be evaluated
as
pr (R∗N = r) =
2rN3




εk,N (αNr − k)N−2, (5.13)
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where εk,N is given by Eq. 5.11.
This is a generalization of Treolar’s representation for the random flight with
equal step sizes [216]. We see that, interestingly, the density of the three-dimensional
case can be expressed in terms of statistical properties of the one-dimensional case.
Integrating Eq. 5.13 term-by-term from r to infinity, we have the following corollary.
Corollary 1. The cumulative distribution function of R∗N under the null hypothesis
can be evaluated as






εk,N (αNr − k)N−1(αNr(1−N)− k). (5.14)
In particular, pr(R∗N > (N + 1)/(2
√
N)) = 0.
Note that because of the representation (5.14) for smaller r successively more and
more terms enter the sum in the calculation of pr (R∗N > r). The numerical accuracy
is therefore higher for larger r, i.e. in the tail of the distribution. The representations
(5.13) and (5.14) therefore allow the efficient computation of exact significance proba-
bilities for the test statistic R∗N for small to moderately large sample sizes N (e.g., for
N . 60 under double precision IEEE 754 arithmetic). This restriction on the sample
size is only due to numerical accuracy; for larger N approximations of the Gamma
function can be used. In figure 5.1 the distribution of R∗N , for some values of N , is
plotted and compared with the asymptotic χ23 distribution. In Table 5.1 the values
of the quantile function are listed. These values have been calculated by numerically
inverting Eq. (5.14) with a bisection method and are conservatively rounded.
Remark 3 (What is tested by the Moore-Rayleigh test?). As in Remark 2, assume
that Xi = RiUi, with Ri ∼ pr and Ui ∼ u, where pr(r) = pr(|Xi| = r) and u(x) =
pr(Xi/|Xi| = x) are arbitrary. If E(Xi) = 0, this implies E(Ui) = 0, and suggests that∑
i Ui ≈ 0 for a sample. More precisely, an upper bound for the variance of the test
statistic R∗N is realized by the one-dimensional Moore-Rayleigh null hypothesis, whose
distribution is similar to the null hypothesis of the three-dimensional case (confer
figure 5.6). Therefore, as in the one-dimensional case, the Moore-Rayleigh test under
the assumption of radial decomposability tests mostly for differences in location. Note
that symmetry of the Ui, i.e. pr(Ui = u) = pr(Ui = −u), implies that E[
∑
i Ui] = 0.
Thus, under the assumption of decomposability, testing for spherical symmetry and
testing for symmetry are approximately equivalent, i.e. the Moore-Rayleigh test will
not be sensitive to deviations from spherical uniformity if the underlying distribution
is merely symmetric or mean-centered. This is actually an advantage when the Moore-
Rayleigh test is considered as a two-sample test (see below).
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Figure 5.1: Left: Distribution function for N = 2, 5, 10 and 50 (solid, from right





To evaluate the performance of the three-dimensional Moore-Rayleigh test (MR3),
power functions for a number of distributions were obtained by Monte-Carlo sim-
ulation. These show the fraction of rejections of the null hypothesis for a specific
distribution, significance level α, and sample size N . The left panel of figure 5.2
shows the power function for a family of diagonal Gaussian distributions with unit
variances, shifted away from zero (along the z-axis) a constant distance µ ≥ 0. Each
point power estimate was obtained by 1,000 realizations of the distributions and rep-
resents the fraction of significance probabilities (“p-values”) less than the nominal
significance level α. The test was performed on N = 10 randomly drawn samples,
and is compared to Hotelling’s (non-randomized) T 2 one-sample test of location [217],
as implemented in the R package ICSNP1, and to the spherical uniformity permu-
tation test of [218], under 104 resamplings. The test statistic of the latter is an
U-estimator of the difference between two probability distributions of vectors, calcu-
lated by a Gaussian kernel with a bandwidth parameter. The choice of the proper
bandwidth is the subject of ongoing research; we show results for the two bandwiths
b1 = 0.25 and b2 = 2.5, and denote the corresponding tests by “Diks1” and “Diks2”,
respectively. In comparison with the T 2 test, MR3 shows larger power, an effect that
is more pronounced for lower significance levels. It is thus a more sensitive measure
of changes in location. Note that this does not contradict the well-known optimality
of Hotelling’s T 2 test for the family of multivariate Gaussian distributions, since in
the calculation of T 2 the covariance matrix needs to be estimated from the data. In
the special case of equal covariances considered here, the Moore-Rayleigh test can
therefore exhibit larger power. Also note that the test of Diks & Tong can be more
powerful than the MR3 test, but as its results depend strongly on the bandwidth
parameter, it is difficult to apply it routinely.
In figure 5.3, power functions are shown for a family of diagonal Gaussian distri-
butions where the standard deviation of one axis was varied from σ = 0.1 to σ = 5.0
in steps of 0.1, the other standard deviations were kept at unity. As expected from
Remark 3, the MR3 test performs poorly for this specific violation of spherical symme-
try. The remaining symmetry in the distribution means that although sample points
are now increasingly less concentrated on one axis, on average their contributions to
the resultant length still mostly cancel each other. Analogously, the T 2 test has only
nominal power for the anisotropic multivariate Gaussian, being a test of location only.
Note that MR3 shows slightly more power than the nominal significance levels α for
σ 6= 1, as do the Diks1 and Diks2 tests.
To assess the effect of asymmetry of the sample distribution, we employ the Fisher
distribution, also known as the Fisher–Bingham three-parameter distribution. This
is the k = 3 case of the k-dimensional von–Mises Fisher distributions commonly used
in directional statistics [210]. Details of its computation are given in the Appendix.
We denote the Fisher distribution with concentration parameter λ (and with the
1K. Nordhausen, S. Sirkia, H. Oja, and D.E. Tyler. ICNSP: Tools for Multivariate Nonparamet-
rics, R-package version 1.0-2 (2007)
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Figure 5.2: Estimated power functions for the family of Gaussian distributions with
covariance matrix the identity and mean shifted a distance µ away from zero. Sample
size N = 10.













































Figure 5.3: Estimated power functions for the family of Gaussian distributions, vary-
ing the standard deviation σ of a single axis. Sample size N = 10. Note the small












Figure 5.4: Scattered Fisher distribution, visualized by 1,000 randomly drawn points
in the unit-cube. Left: Concentration parameter λ = 1. Middle: Concentration
parameter λ = 2.5. Right: Concentration parameter λ = 5.
choice ξ = e3) by F3λ. To avoid degeneracies due to its singular character, the
F3λ distribution is multiplied by 1 − Z, where Z ∼ N (0, 0.1). Figure 5.4 shows
three examples of N = 1, 000 random variates obtained from these “scattered” Fisher
distributions for distinct values of the concentration parameter λ, with increasingly
larger deviation from the uniform distribution. The power of MR3 for the family
of scattered Fisher distributions, varying the concentration parameter, is comparable
to the power of the other tests (not shown). Let us now consider a mixture, where
the samples are chosen either (i) from the uniform distribution on the unit sphere,
or (ii) from the scattered Fisher distribution 2F35. The probability 0 ≤ p ≤ 1 for
each sample vector to be chosen from the second distribution is the parameter of
this family of mixture distributions, with larger p indicating stronger deviations in
uniformity for the larger vectors. Figure 5.5 depicts the estimated power for this
family under variation of the mixture probability p. Compared to the T 2 test, the
MR3 test is seen to be more sensitive to these specific departures from uniformity.
It should be noted that reversing the situation, e.g., by considering F35/2 instead of
2F35, such that the smaller vectors exhibit deviations from uniformity, the power of
MR3 becomes less than that of the T 2 test (not shown).
5.3 The two-sample test
The most interesting application of the Moore-Rayleigh test is the two-sample prob-
lem. There, we are given two vector-valued random variables
X = (X1, . . . , XN ) and Y = (Y1, . . . , YN ), (5.15)
and we assume that they are identically and independently distributed with densities
f and g, respectively. The differences Yj −Xi are then distributed according to the
62
The generalized Moore-Rayleigh test















































Figure 5.5: Estimated power functions for the mixture of the scattered Fisher dis-
tribution 2F35 with the uniform distribution on the sphere S
2, varying the mixture
probability p that a sample vector arises from the first distribution. Sample size
N = 10.
convolution g ∗ (−f), whose density is
pr (Y −X = x) =
∫
pr (Y = u) pr (X = u+ x) dku. (5.16)
Under the null hypothesis that the Xi and Yj come from a common probability density
f , this reduces to the symmetrization of f , with density
pr (Y −X = x) =
∫
pr (X = u) pr (X = u+ x) dku. (5.17)
If the probability density f is spherically symmetric around its mean µ, i.e. uniform on
each hypersphere {x | ||x−µ|| = r}, then Eq. (5.14) gives the significance probability
of a deviation from the null hypothesis. In particular, this applies when f is assumed
to arise from a multivariate normal distribution, justifying the use of the Moore-
Rayleigh statistic in many practical situations.
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5.3.1 Testing for symmetry
In general, however, the distribution of h = f ∗ (−f) is merely symmetric, i.e. h(x) =
h(−x) for all x ∈ Rk. This follows from∫
pr (X = u) pr (X = u+ x) dku =
∫
pr (X = u) pr (X = u− x) dku. (5.18)
The following demonstrates the difference.





δx is the Dirac measure concentrated at the point x ∈ Rk. The distribution Bx leads
to an embedding of the one-dimensional Moore-Rayleigh null distribution in three-
dimensional space. Its realizations take values x and −x with equal probability, and
it is not spherically symmetric. As it is, Bx is neither absolutely continuous, nor
can it arise as the the symmetrization of a distribution. Nevertheless, it is a model
for a distribution that can arise in practice: First, the delta distributions can be
approximated, e.g., by a series of Gaussian distributions with decreasing variance.
Secondly, consider the singular distribution Bx that is concentrated on a line {λx |
λ ∈ R} ⊆ Rk through the origin. Applying the Moore-Rayleigh test to Bx is equivalent
to calculating the test statistic from B1, since B
x is invariant under symmetrization
and is projected, before ranking, to the sphere S0 = {−1,+1}.
The distribution B1 is a representative of the class of “fastest growing” random
flights in three dimensions, since any other distribution of increments has less or equal
probability to reach the highest values of the test statistic. On the other hand, the
uniform distribution on the sphere, which represents the null hypothesis of the Moore-
Rayleigh test statistic R∗N , will attain lower values of R
∗
N with higher probability, as
the uniform random walk can do “orthogonal” steps that increase the distance from
the origin faster than in B1 (on the average). To be specific, if the finite sample X is
distributed according to B1, the n-th step of the scaled random walk either increases
or decreases the distance from the origin by n (when crossing the origin, there is
an obvious correction to this). However, if the n-th step were taken in a direction
that is orthogonal to the resultant obtained so far, the distance will increase from R
to
√
R2 + n2 ≈ R + n/(2R), with probability 1 (conditional on the orthogonality).
Figure 5.6 compares significance probabilities for B1 with those of the uniform random
flight that represents the null hypothesis of the Moore-Rayleigh test, for N = 10
sample points. There exists a value of the test statistic where the two curves cross (at
about p = 0.20), and after which the distribution function (significance probability)
of the one-dimensional random walk B1 lies below (above) the one for the uniform
random flight. The two-sample Moore-Rayleigh test, interpreted as a goodness-of-fit
test, is therefore liberal, although it escaped Moore from his attention. This has
also proven for the Wilcoxon signed-rank test, the equivalent of the one-dimensional
Moore-Rayleigh test [219,220]. These findings have casted doubt on the applicability
of the test in this setting.
64
The generalized Moore-Rayleigh test



































Figure 5.6: Comparison of significance probabilities for resultant lengths of spherically
symmetric (smooth curve) and one-dimensional symmetric random walk (piecewise-




The optimal upper bound for a conservative significance probability would be
G∗N (r) = sup
ΨN
pr(|SN | ≥ r), (5.19)
where the supremum is taken over the set ΨN of all possible symmetric probability
distributions for N increments. More precisely, these increments are not independent
but arise from a mixture of independent distributions by the order distribution (due
to the ranking of vector lengths) of their radial projections. Even if one restricts this
to the class where only independent, not necessarily identical symmetric probability
distributions for each step are considered, this is a difficult problem. First steps in this
direction have been made by [221], where the three-dimensional problem is reduced
to a similar problem in one dimension by the familiar tangent-normal decomposition
of the sphere. Apart from that, there has not been much progress in determining
the envelope in Eq. 5.19. Even in the one-dimensional case it is not clear what
the “fastest” random flight with linearly bounded increments is. If a liberal test is
admissible for the specific problem at hand, e.g., in exploratory data analysis, MR3
offers an efficient two-sample test. Moreover, the Remarks and figure 5.3 suggest
that the significance probabilities are only liberal for relatively large values of the
test statistic. Studies with synthetic data seem to confirm that the MR3 test fails
gracefully, if at all, for distributions expected in biomedical imaging practice [36].
Since the assumed null hypothesis is stronger than mere symmetry, MR3 can also
be used for negative testing, i.e., if the null hypothesis of the uniform random flight
cannot be rejected for a sample of difference vectors, then the modified null hypothesis
that g ∗ (−f) is symmetric, not necessarily spherically symmetric, cannot be rejected.
For the null hypothesis of mere symmetry, there does not exist an accessible sufficient
statistic and existing tests are either only asymptotically nonparametric or require
further randomization of the underlying distribution [218, 222–226], so the MR3 test
offers a simpler and much more efficient alternative, albeit with the disadvantage that
it is potentially liberal.
5.3.2 Further issues
A different issue with the Moore-Rayleigh test arises in the (usual) case of unpaired
samples. The two sample test we have presented up to now assumes paired vectors,
and this approach reduces the symmetry group of the null hypothesis from the group of
permutations to the much smaller group of reflection symmetry of the given pairs. The
main reason here is simplicity in applications and reproducibility of the test statistic.
If there is no natural pairing, it seems advisable to randomly pair samples, as e.g. [200]
advocates. However, a drawback is that the test statistic then becomes a random
variable, and replications of the test will result in distinct significance probabilities.
This is undesirable, for example, in a clinical context. Bootstrapping the test, i.e.
considering the mean of the test statistic R∗N obtained during a large enough number
of resamples from the empirical distributions, is a natural way to obtain more or less
replicable significance probabilities, but on the expense of computational time. It
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Figure 5.7: Estimated power for translated (10 standard deviations), then rotated
diagonal Gaussians with unit variances as a function of relative rotation angle. Sample
size N = 10.
is also not precisely known at present what the convergence properties of such an
estimator are. A different approach would be to pair samples based on a measure
of optimality. This seems natural enough, but has the undesirable feature that the
test might become biased, e.g., too sensitive in case the sample points are matched
by the method of least-squares or the Wasserstein distance. Therefore, as a practical
solution in a context where reproducibility is desired, we propose to pair samples
based on their ranks, such that X(i) is matched with Y(i), i = 1, 2, . . . , N (with ties
resolved arbitrarily). Under the null hypothesis, the decomposability of the common
distribution of X and Y guarantees the asymptotic unbiasedness of this approach,
although for finite samples a slight bias is expected.
5.4 Results
5.4.1 Simulation results
In this section we show the results of a number of numerical simulations for the two-
sample problem and compare them with Hotelling’s T 2 test and the Diks1 and Diks2
tests. Throughout, we use random matching of samples and N = 10. Figure 5.7
shows the results for two standard Gaussian distributions that were first translated
in the same direction by ten standard deviations, and then one of them was rotated
against the other (with the origin as the center of rotation), for 1, 000 realizations.
The Moore-Rayleigh test performs well: Its power for the trivial rotation is nominal,
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Figure 5.8: Estimated power functions for translated (10 standard deviations), then
rotated diagonal Gaussians with unit variance against the scattered Fisher distribu-
tion (scaled by a unit Gaussian) as a function of relative rotation angle. Sample size
N = 10. Note the small power at angle zero.
and for larger rotation angles higher than the power of the T 2 test. Similar results are
obtained when rotating Fisher distributions (not shown). Note that the Diks1/Diks2
tests are performed on the group of symmetric sign changes (of order 210), in contrast
to the previous section where the full symmetry group of all rotations (of infinite order)
was used, and do not resolve significance probabilities smaller than 1/1,000, i.e. their
power is zero for the lower significance levels, and therefore not indicated. Figure 5.8
compares the Gaussian distribution with the distribution R ·F3λ, R ∼ N (0, 1), when
both distributions are first translated and then rotated against each other, with similar
results. Finally, figure 5.9 shows adjusted p-values, for 104 permutations and 100
realizations each. The Moore-Rayleigh test again shows slightly better power then
the T 2 test. More importantly, there is not much difference with the unadjusted
power functions. These results are based on 100 realizations only, to speed up the
considerable amount of computations, which accounts for the visible fluctuations.
5.4.2 Synthetic data
As remarked in the introduction, an important field of application of the Moore-
Rayleigh test is the morphometric analysis of magnetic resonance (MR) images.
Therefore, a synthetic data was generated simulating two groups of images with
inter- and intra-variations: The Moore-Rayleigh test was validated on a synthethic
50Ö50Ö80 three-dimensional image domain. Five spherical deformations were added
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Figure 5.9: Adjusted estimated power functions. Left: translated (10 standard devi-
ations), then rotated diagonal Gaussians with unit variances as a function of relative
rotation angle. Right: translated (10 standard deviations) then rotated diagonal
Gaussians with unit variance against the scattered Fisher distribuion (scaled by a
unit Gaussian) as a function of relative rotation angle. Sample size N = 10. Results
based on 100 realizations of 104 permutations each.
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Figure 5.10: Generation of spherical deformations. The plot shows the behaviour of
the deformation field in a one-dimensional projection along a radial direction. The
volume at normalized distance r/R from the centerpoint of the sphere (radius R) is
mapped radially to r′/R. For r < R/2 the length of the deformation vectors expands
linearly, r′ = λ1r, attaining its maximum at half radius r = R/2. For r > R/2 the
length shrinks linearly by λ2 = 2 − λ1, ensuring continuity at the boundary. The
stippled line shows the case of no deformation (λ1 = 1).
in two distinct regions, introducing characteristic localized changes. The volume in
each sphere was mapped radially, linearly expanding by a factor λ1 = 1.8 from the
centerpoint to half radius distance, and then contracting linearly by λ2 = 2− λ1, re-
sulting in a one-to-one transformation of each spherical volume. Although the trans-
formations were not smooth, interpolation at subpixel level guaranteed that they were
indeed local diffeomorphisms. Figure 5.10 shows the transformation along a radial
direction. A Gaussian noise process (zero mean, SD = 1.0) was added to the deformed
image, for a total of 15 distinct realizations, thereby simulating natural variation in
brain structure.
Figure 5.11(A) shows the average lengths of deformation vectors in this image set.
In the upper part (Region 1) one sphere of radius 9 voxels (S2) and two spheres of
radius 6 voxels (S1 and S3) were created at successive distances of 12.5 voxels between
their center points, creating a more complex deformation due to partial overlap in
the superposition of deformation fields. Two spheres in the lower part (Region A)
with radii 6 voxels (S4, left) and 9 voxels (S5, right) were created at a distance of 25
voxels. A second group of 15 images was created, with a reduced radius of 6 voxels for
the spheres S2 and S5. Figure 5.11(B) depicts the absolute differences in deformation
vector lengths between the average deformation fields of both groups in the central
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slice. For the evaluation of the statistical tests, ground truth, i.e. voxels for which the
null hypothesis of no group difference should be rejected, was taken to be the total
volume of the two spheres S2 and S5. This approximation allowed the estimation of
precision and recall from the numbers of true positives (TP), false positives (FP, type








The results are shown in figure 5.12 and table 5.2 for different significance levels
α. The rightmost level α = 2.5 ·10−7 corresponds to 0.05 under Bonferroni correction
with 200,000 voxels. The performance of all four tests is comparable, with the Moore-
Rayleigh test exhibiting better recall and precision rates then the other tests. Note
that the results of the permutation version of Hotellings T 2 test are limited by the
number of relabelling (N = 10, 000), such that Bonferroni correction for multiple
comparisons did not result in any significant voxels.
5.5 Discussion
It is possible to test spherical symmetry in three dimensions with high numerical ac-
curacy by using the combinatorial sum representation given in Eq. (5.14). In combi-
nation with Kahan summation [227], this representation makes it feasible to routinely
calculate p-values for finite sample sizes that allow to assess statistical significance.
Even for hundreds of thousands of multiple comparisons with a Bonferroni correction,
as is common practice in neuroscientific imaging applications, the proposed approach
is effective. Permutation methods, although theoretically preferred, are difficult to
use in this setting due to practical limitations. The standard approaches to cope
with these limitations, based on either saddle-point approximations to permutation
tests [228] or on permutation tests for linear test statistics, where the conditional
characteristic function can be rewritten as a convergent approximating series [229],
are not directly applicable because these statistics usually do not arise in these prac-
tical problems or are too involved in the multivariate case. An alternative might
be the use of optimal (Bayesian) stopping rules in the resampling process [230, 231].
However, small sample sizes can still seriously restrict the possible range of the signif-
icance probabilities. In the special case of the two-sample problem, the distribution
of the null hypothesis is conditional on the unknown distribution of the data, and
the generalized Moore-Rayleigh test is only approximately valid, a feature that all
other (non-randomized) tests of symmetry exhibit. In Section 5.4.2 we evaluated the
properties of this generalized Moore-Rayleigh test empirically with simulated imaging
data of known ground-truth and by comparison with other nonparametric tests; for
further comparisons see [36]. Even though the test is theoretically liberal, it seems
to work well when applied for deformation-based morphometry, as it is not overtly
sensitive to the difference between symmetry and spherical symmetry. An exact test





0.100 0.010 0.001 4 5 6 9 12 15 18
2 1.013 1.056 1.061
3 0.973 1.100 1.138 1.150 1.153 1.155
4 0.948 1.116 1.189 1.222 1.237 1.244 1.250
5 0.930 1.124 1.221 1.275 1.304 1.321 1.338 1.341 1.342
6 0.916 1.129 1.245 1.314 1.357 1.384 1.418 1.427 1.429
7 0.905 1.132 1.262 1.344 1.398 1.435 1.488 1.505 1.510 1.511
8 0.897 1.133 1.275 1.368 1.432 1.477 1.549 1.576 1.586 1.588
9 0.890 1.134 1.284 1.387 1.460 1.513 1.603 1.640 1.656 1.659
10 0.885 1.134 1.292 1.402 1.483 1.543 1.649 1.698 1.720 1.726
12 0.877 1.133 1.303 1.426 1.519 1.590 1.727 1.797 1.834 1.844
14 0.871 1.133 1.310 1.443 1.545 1.626 1.788 1.879 1.931 1.946
16 0.866 1.132 1.316 1.455 1.565 1.654 1.838 1.947 2.013 2.033
18 0.863 1.132 1.320 1.464 1.580 1.675 1.878 2.003 2.083 2.108
20 0.860 1.131 1.323 1.472 1.593 1.693 1.911 2.051 2.144 2.174
30 0.851 1.129 1.331 1.493 1.629 1.746 2.016 2.209 2.350 2.399
40 0.847 1.128 1.335 1.503 1.647 1.771 2.071 2.294 2.467 2.529
50 0.844 1.127 1.337 1.509 1.657 1.787 2.103 2.347 2.540 2.612
60 0.843 1.126 1.338 1.513 1.664 1.797 2.125 2.382 2.590 2.668
∞ 0.834 1.123 1.345 1.532 1.697 1.846 2.233 2.559 2.847
Table 5.1: Critical values of Moore-Rayleigh statistic in 3D for various sample sizes
N.
Test
α = 0.05 α = 0.01 α = 0.005 α = 0.001
Prec. Rec. Prec. Rec. Prec. Rec. Prec. Rec.
MR3 0.07 0.81 0.21 0.63 0.59 0.39 1 0.04
HT2 0.07 0.77 0.21 0.54 0.56 0.28 1 0.01
permuted HT2 0.07 0.77 0.21 0.54 0.57 0.28 0 0
Diks1 0.03 0.38 0.1 0.23 0.35 0.11 0.69 0.04
Diks2 0.07 0.80 0.22 0.59 0.56 0.31 0.77 0.08
Table 5.2: Precision and recall for the synthetic dataset.
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slightly improved power when compared with conventional permutation testing. This
can be used in a second stage after initial screening with the fast, unadjusted Moore-
Rayleigh test. Although such screening could also be realized by the T 2 test, the MR3
test seems better suited to this problem due to its enhanced power, which allows for
strong control of the family-wise error. In contrast, the T 2 test does often not allow
the localization of individual voxels, as demonstrated in the example on deformation
morphometry in brain scans. It should be noted that we have only considered the
conservative Bonferroni correction here, for simplicity, but it is expected that the
MR3 test remains a more sensitive instrument also under modern step-down multi-
ple comparison procedures (as described in, e.g., [196]). An implementation of the
Moore–Rayleigh test as a package for the statistical computing environment R2 or
implemented in C++ is available on request.
5.A The Fisher distribution
The Fisher distribution is a singular distribution on the hypersphere Sk−1 whose
density f(x), x ∈ Rk, is proportional to eλξtx, where ξt denotes the transpose of ξ.
The mean direction ξ is constrained to be a unit vector, and λ ≥ 0 is a concentration
parameter. Without restricting generality, we let ξ = ek be the unit vector in the
k-th dimension, so f ∼ eλxk only depends on the last coordinate, and we are left with
a one-parameter family of distributions. Following [232] and [233], a random variate
distributed according to the von–Mises Fisher distribution is obtained by generating
a random variate W for the last coordinate, by the density proportional to
eλw(1− w2)(k−3)/2, w ∈ (−1, 1), k ≥ 2,




1−W 2 · V t,W ) ∈ Rk
then has the desired density. In k = 3 dimensions the former can be achieved by
integrating the distribution function of W directly. Choosing a uniform variate U on





2The code can be downloaded from http://folk.ntnu.no/muskulus/
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Figure 5.11: Validation with a synthetic dataset. A slice from the deformation field
of 50Ö50Ö80 voxels (isotropic spacing of 1.00 mm), showing the five spherical defor-
mations that were added to it (see text for details). The color indicates the length
of the deformation vectors per voxel. A: Mean deformation field for the first group.
B: Difference between deformation fields for the two groups (smaller deformations in
spheres S2 and S5 in the second group).
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Figure 5.12: Validation with a synthetic dataset. Negative logarithms of significance
probabilities for two-sample Moore-Rayleigh test (MR3), the Diks2 test (see text for
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Chapter 6
abstract: Non-rigid registration of MR images to a common ref-
erence image results in deformation fields, from which anatom-
ical differences can be statistically assessed, within and between
studies. Without further assumptions on the underlying distribu-
tions, nonparametric tests are needed and usually the analysis of
deformation fields is performed by permutation tests. However,
permutation tests are computationally expensive and have limi-
tations by sample size and number of iterations. In this paper,
we consider a single nonparametric test as an alternative for per-
mutation tests; the 3D Moore-Rayleigh test. As its distribution
function is available in closed form, permutation testing can be
avoided. Furthermore, the test incorporates both the directions
and magnitude of the deformation vectors to attain a high power.
Using synthetical and clinical data we show that the performance
of the Moore-Rayleigh test outperforms the classical permutation
test and significantly lowers the computational time as it is not
dependent on the randomization of the data.
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6.1 Introduction
Quantifying group differences between cases and controls gives insight in the devel-
opment and progression of diseases. In brain research, Magnetic Resonance Imaging
(MRI) is considered a useful tool for studying various aspects of diseases. Among
others, brain morphometry has been exploited to indicate differences within and be-
tween groups of patients and controls [234]. Brain morphometry can be divided in
three different groups: volume-based morphometry (VBM), shape-based morphome-
try (SBM), and deformation-based morphometry (DBM) [235]. SBM quantifies differ-
ences by shape parameterizations of the segmented brain structures [236–239], which
is generally restricted to a few structures. VBM, also referred to as voxel-based mor-
phometry [27, 240], is capable of analyzing the whole brain by quantifying the ratio
of grey-matter, white-matter, and cerebrospinal fluid in each voxel.
Although both methods work very well for human subjects, in mice the segmen-
tation of brain structures into gray and white matter is still challenging [28]. DBM
offers an elegant solution to avoid segmentation by exploiting nonlinear registration
to a common average and analyzing the resulting deformation fields [241], where the
Jacobian matrix of a deformation vector encodes for the volume change of a voxel and
is therefore a measure for shrinking or expansion of brain structures. DBM has been
exploited to determine intra-group variation at a single timepoint [6,242] or in longi-
tudinal studies [243]. Inter-group variation can be determined by, e.g. the application
of Hotelling’s T 2 test (HT2) on the Jacobian [194] or directly on the deformation field
vectors [195]. Studholme et al. presented a multi-variate linear model to detect the
relationship between environmental variables (such as diagnosis, age and risk fac-
tors) and local brain shape changes [244]. Inter-group variation is assessed by the
analysis of covariance (ANCOVA) of the multi-variate linear model in alcohol abuse
patients [245] or in transgenic mice models [38]. Multi-variate parametric tests make
assumptions of the underlying distributions, such as normality or equal variances.
When these assumptions are not met, parametric tests might become unreliable.
Nonparametric test, with their minimal assumptions, provide an alternative for
quantifying group differences in DBM. Permutation tests, for instance, provide an
exact test for the quantification of group differences, with the only assumption that
the groups are exchangeable under the null hypothesis. The performance of the
Permutation tests depends on the selection of the test statistic, which has to be
chosen so it best represents and separates the data: For instance, in the analysis of
3D deformation fields, the HT2 has been applied for the quantification of the local
group differences [39, 194] or the partial least squares method on the Jacobian [246].
A disadvantage of the permutation tests is that their minimal significance probability
(p-value) is bound by the number of iterations i and the sample size of groups (n and
m): Randomly relabeling the two groups results in maximal K = (n+m)!2(n!m!) different
combinations. If K <= i, the original setting occurs by chance around iK + 1 times,
resulting in a minimal p-value of p & i+KK·(i+1) . This formula also shows the dependency
of the minimal p-value on the number of iterations: In the case that n → ∞ and
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m→∞, the p-value is still limited by 1i+1 .
Example 3. Consider 4 samples from a standard normal distribution in 2D:
X = {(1.7,−0.2), (0.7,−1.2), (1.2, 1.9), (1.1, 3.0)}
Y = {(3.7,−0.2), (2.7,−1.2), (3.2, 1.9), (2.1, 3.0)}
Here, Y is equal to X with a shift in the x-coordinate of 2 units. Testing for a
group difference would be found significant by the HT2 with a p-value of 0.0068. If
significance would be tested with permuations of the HT2, this differences would be
found not significant with a p-value of ∼ 0.0287, which can be determined by the
following calculation: With the sample sizes of n = m = 4, the maximal amount of
combinations that can be made is K = (8)!2(4!4!) = 35. Therefore, if permutations with
i = 10, 000 relabelings are applied, the original setting, as given above, appears by
chance approximately iK + 1 =
10,000
35 + 1 = 287 times.
Thus, p ≈ i+kk·(i+1)10, 035/(35 · 10, 001) = 0.0287.
The example shows the nature and disadvantage of permutation tests. For an
accurate calculation of the probability to reject the null hypothesis a sufficiently large
sample size is needed, but when the sample size increases, the number of permutations
will become the limiting factor and has to be increased too. When the sample size
has grown sufficiently large ((n = m) ≥ 100), the permutation test can be approx-
imated by the standard t-test [198]. As sample sizes of 100 subjects are rare in an
experimental setting, the highly computationally expensive permutation tests need
to be performed. To lower the computational load of permutation testing, optimal
stopping rules have been developed, although not (yet) put to practice [230,247].
Despite the computational load, permutation testing on mean-based statistics,
like Hotellelling’s T 2 test, are popular in DBM. Firstly, because it still gives sufficient
power to perform DBM, secondly, because the test fails gracefully in the case of a
violation against the assumptions of the test statistic, and thirdly, by lack of another
method of similar or improved power. Permutation tests with nonparametric test
statistics, such as the Brunner-Munzel statistic [248], have already been considered
for the quantitative groupwise comparison in functional Magnetic Resonance Images.
Despite the nonparametric nature of the Brunner-Munzel statistic, Rorden et al. found
that it could only outperform permutations with a t-test in a few cases as the t-test
is relatively robust for violations in the assumptions.
In previous work [249], we generalized the two-dimensional Moore-Rayleigh test
[200] to arbitrary dimensions. Furthermore, we have given the three-dimensional
Moore-Rayleigh test (MR3) in closed form and we discussed the implications of the
test in the two-sample problem. On synthetic data we have shown that the MR3 can
be used for deformation-based morphometry and is robust for noise and applied regis-
tration algorithm [36]. In summary, it’s advantages are threefold: (a) randomization
of the statistic is not necessarily since the Moore-Rayleigh test is fully nonparametric;
(b) the vector length and direction are directly incorporated in the test. (c) the re-
sulting p-values of the Moore-Rayleigh test might be very low, which allows correction
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for multiple tests, including the highly conservative Bonferroni correction.
In this work, we demonstrate how the MR3 can be exploited for regional quan-
titative morphometry of mouse brain MRI and how it compares to permutations of
the Hotelling’s T 2 test (pHT2). First, we shortly explain the principle of the MR3
and how it can be exploited for DBM. Afterwards we illustrate the behavior of the
MR3 and the pHT2 by simulating situations that might occur in a deformation field
and compare the power of both tests. Afterwards we apply both tests on real data,
the transgenic APP23 mouse and its wild types. At the end of the paper, the Moore-
Rayleigh test and its implications for deformation based morphometry are discussed.
6.2 Method
6.2.1 Formation of deformation fields
Consider two sets of 3D MR images taken from different populations of equal size.
The first step in the analysis is to affinely register the images to an average A. This
normalization step brings all images to the same coordinate system and removes all
non-specific anatomical differences, like global orientation and scaling. From now on,
we consider only the normalized sets of images I = (i1, ..., in) and J = (j1, ..., jm). A
non-rigid registration defines the relation between the average and an image i, which
is found by the minimum of a similarity measure ρ:
Ti = min ρ(i, A) (6.1)
Assuming that there is no misregistration, Ti indicates the local anatomical differences
between i and A, which are coded by vectors in R3. Non-rigidly registering image
sets I and J to the A results in two sets of deformation fields TI = (Ti1 , ..., Tin) and
TJ = (Tj1 , ..., Tjm) for each homologous point in the average.
Assumption 1. If all images in I belong to the same population as the subjects used
to generate A (or A is the result of averaging the subjects from I), TI represents
the intra-group variation and noise. This results in vectors that are randomly spread
around each point in A.
Assumption 2. If all images in J do not belong to the same class of the subjects used
to build average A, TJ represents besides the intra-group variation and noise, also the
inter-group variation between J and A. In case of a groupwise shape difference at a
certain point x, the deformation vectors are likely to be not randomly spread around
x, but indicate the direction of the shape difference.
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6.2.2 3D Moore-Rayleigh test
The 3D Moore-Rayleigh test (MR3) is a nonparametric test for spherical symmetry1
of a group of three-dimensional real-valued vectors [36, 249]. Assumption 1 and 2
justify the MR3 on the separate voxels of the deformation fields:
To calculate the MR3 statistic for a single group of vectors, the first step is to
scale the N vectors by the rank of their lengths, where X(1) is the smallest vector
of length 1 and X(N) is the largest vector of length N . Under the null hypothesis,
this ensures the nonparametric properties of the test. The summation of the ranked







The length of the resultant, ‖RN‖ has a range of [0,
∑N
n=1 n], as X1, ..., XN are scaled
by their ranks. Under the null hypothesis, ‖RN‖ will be small and large values
indicate the random flight is biased, i.e. most vectors point in the same direction.
This test statistic is subject to the Moore-Rayleigh test, as described in more detail
in section 5.2.2.
To test if a group of images I is significantly different from A, each separate voxel
is tested by the Moore-Rayleigh test, as given in equation 6.2. For each voxel the
following null hypothesis (H0) can be formed.
H0 : the probability density distribution of the deformation vectors is spherically symmetric,
i.e. the elements of the vectors are drawn from a multivariate normal distribution. .
The p-value of the Moore-Rayleigh test indicates the likeliness that, under the null hy-
pothesis, the ‖RN‖ for a certain voxel is returned and thus according to assumption 1
the likeliness that at this location no shape difference between I and A is found.
6.2.3 3D Moore-Rayleigh test for groupwise comparison
To test two I and J for group differences, their voxelwise relationship to A can be
exploited:
Proposition 3. If TI and TJ are drawn from a spherically symmetric distribution,
than the differences between I and J are also spherically symmetric distributed.
This proposition implies that in case J is from the same population as I and
A, the difference vectors between I and J must also be randomly distributed, as
illustrated in figure 6.1(a). In case J is from a different population with a local shape
difference in voxel x, the difference vectors will not randomly be spread around the
origin, as shown in figure 6.1(b). It has to be noted that in theory these difference
1Vectors in a vector field are spherical symmetrical, if their magnitude and orientation (inward
or outward) is uniformly distributed and only depending on the distance to the origin.
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(a) (b)
Figure 6.1: The deformation fields of a control group (black) and the test group (dark
grey) for one voxel (n = m = 10), where the difference vectors, see text for details,
are given in dotted arrows. The right frame shows the difference vectors translated
to the origin to show the spread of the differences. This situation is given for two
differences in means: ∆µ = 0 (a) and ∆µ = 2σ (b).
vectors are merely symmetric instead of spherical symmetric and therefore, the Moore-
Rayleigh test might be potentially liberal [249], although this could not be detected
by simulations on synthetic data [36].
The application of the MR3 on the vector fields is only valid if the right average
has been created, as described in remark 4. If this requirement is not met, systematic
differences between the control group and the average might be picked up and might
be wrongly interpreted as differences between the control and the test group. An
average can be created by simultaneously and iteratively registering a population of
images to generate a true and new average [5], or by using the leave-one-out method,
which ensures unbiased warping of controls to an average. The images of the mutants
are afterwards matched to the whole average of controls.
Remark 4. The average that is used to test for significant group differences between
two populations must be created from subjects belonging to the same population as
the control group.
The vectors in the deformations fields are voxelwise tested by the Moore-Rayleigh
test on the following null hypothesis:
H0 : There is no group difference between I and J, therefore the probability density
distribution of the differences of the deformation vectors is spherically symmetric.
The differences between I and J can be calculated in multiple ways [249]. For an
asymptotically unbiased approach, the vectors can be matched by bootstrapping: For
the same voxel, the vectors are randomly matched resulting in a value for ‖RN‖. This
process is repeated i times, resulting in i values for RN . The MR3 is calculated for
the median of the resulting ‖RN‖s. Although this method is unbiased, it converts
the test statistic ‖RN‖ to a random variable and the Moore-Rayleigh test will not
be repeatable. Therefore we propose to match the deformation vectors in each voxel
according to their rank, where the largest vector in I (I(N) is matched to the largest
vector in J (J(N), as shown in equation 6.3. Under the null hypothesis of spherical
symmetry, this approach is unbiased for large sample sizes. However, in finite data set
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If two groups have unequal sample sizes it is advised to match on the highest rank
is, as the largest deformation vectors usually code for group difference. A disadvantage
of this approach is that the test might have a higher sensitivity for outliers especially
in ex vivo imaging [6]. Therefore, in data with a high noise level, one can also decide
to match on the one but highest rank in the case of unequal sample sizes. In this
paper, however, we address only the case of equal sample sizes N = min(n,m).
6.2.4 Violations against the assumptions
Nonparametric methods make only minimal assumptions on the underlying data, such
as continuity or symmetry (exchangeability). To justify the application of the Moore-
Rayleigh test on clinical data, one main assumption is made on the data: It is assumed
that if the average is representative for the the control group, the deformation vectors
of nonlinear registration of the controls to the average leads to spherically symmetric
distributed vectors.
In mouse studies, the genotypes of the subjects can be controlled and are, there-
fore, very similar. Yet, due to dehydration of the mice prior or during scanning or
other influences, might cause this assumptions to be violated [180]. Violations against
the assumptions of the MR3 can be easily found with the application of the one sam-
ple MR3 on the deformation vectors of the control group. If for a voxel a p-value
is found found that is smaller than a predefined critical value α, the null hypothesis
of spherical symmetry is rejected. For these voxels the assumptions are violated and
the the MR3 cannot be applied directly as it might be too liberal. These particular
voxels can be handled according to the following procedures:
Exclusion
By excluding the voxels that violate against the null hypothesis from the analysis, it
is certain that no incorrect conclusions are drawn.
Randomization
The framework of permutation testing provides an exact test without prior assump-
tions on the data besides exchangeability. Therefore, the ‖RN‖ can be used as test
statistic in permutation tests, thus allowing to incorporate the MR3 without further
assumptions on the data.
6.3 Results
In this section we evaluate the power of the Moore-Rayleigh test with the vectors
paired by their rank (MR3) and the permutation test using the Hotelling’s T 2 test as
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test statistic with 10,000 relabelings (pHT2) for comparison purposes [39] on simula-
tion data in section 6.3.1 and on experimental data in section 6.3.2.
6.3.1 simulation data
The type 2 error is also called the power of a statistical test, indicated by β and is
defined as the fraction of rejections of the null hypothesis at a certain significance
level α. The power of the proposed tests is evaluated by monte carlo simulations on
simple simulations of practical situations, with α fixed at 0.01.
Discrimitating power
Assuming that the intra-variation of the control group and the mutants are spherically
symmetric, 2 gaussian points clouds in 3D were simulated defined by a mean (µ) and
standard deviation (σ). Each point x in a cloud represent a deformation vector from
the origin to x. A group difference is simulated by a difference in the means of the
two point clouds, i.e. ∆µ > 0. The discriminating power of MR3 and the pHT2
was calculated for various differences in mean (0 ≤ ∆µ ≤ 10σ), while the standard
deviation was kept constant (σ=1.0) for both groups. For each value of ∆µ, N points
were randomly drawn from the two distributions, which were afterwards tested for
group difference by the three tests, where N = {5, 7, 10, 20}. This was repeated a
1,000 times. The power for ∆µ is estimated by the ratio of the number of rejections
of the null hypothesis (group difference detection) to the number of iterations.
Violations to the assumptions of spherical symmetry
To show the robustness of the MR3 to violations to the null hypothesis, two gaussian




2σz with sample sizes N = {5, 7, 10, 20}.
Two power tests were performed: The first one tests the performance when the main
direction of variance is in the direction of the group difference, therefore ∆µ was
varied from 0 (completely overlap) to 10σx (completely separated) in the x direction.
The other test was analyzing the performance when the main direction of variance
was perpendicular to the direction of the group difference, therefore ∆µ was varied
from 0 to 5σy (completely separated) in the y-direction.
Results
In figure 6.2 the power functions for the MR3 and pHT2 are shown for sample sizes
of N = {5, 7, 10, 20}. In case of no violations against the null hypothesis, the MR3
has a better performance than the pHT2 when the sample sizes are small. This effect
fades out if the samples per group are larger than 10. In case the assumptions of
spherical symmetry are violated, shown in figure 6.3, both the MR2 as the pHT2
seem to fail gracefully, i.e. the tests will become more conservative. Interestingly,
in case the violations against the assumptions are in perpendicular direction of the
group differences (figure 6.3(B, D, F, and H) ), the MR3 becomes more conservative
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Figure 6.2: The estimated power for the discrimination of two gaussian spheres with
σ = 1 and relative displacement of ∆µ with N = 5 (A), N = 7 (B), N = 7 (C) and
N = 20 (D).
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than the pHT2. In the case that the violations against the assumptions are in the
same direction of the group differences, the MR3 is outperforming the pHT2. In the
case of extreme small sample sizes (shown in figure 6.2 (A) and figure 6.3 (A and B))
the pHT2 have limited power .
6.3.2 Experimental application
Image formation
In this study, we compared the APP23 mouse brain with control mice. The APP23
is a transgenic mouse model for Alzheimer’s Disease, which expresses the deposit of
amyloid plaques in the brain and its vascular structure, resulting in brain atrophy
in the cortex, hippocampal region and cerebellum [89,103]. Atrophy in these regions
causes enlargement of the ventricles from 6 months onwards, for more details see
section 3.2. Due to this well known pathology, this dataset is suitable for validation
purposes of the MR3 and to compare its performance to the performance of the pHT2.
For the experiments, 6 APP23 mice and 6 controls from the same or parallel lit-
ters were considered. Mice were hemizygous for the transgene of interest. Animals
were housed under standard conditions and fed a standard diet and water supply ad
libitum. Animal handling, care and experimental use have been performed in line
with the Swiss Federal Law for animal protection (animal licenses BS No. 1094 and
1283). The mice were imaged at the age of 19.7 ± 0.45 months, their age-matched
non-transgenic littermates served as controls. For the MRI investigations, the animals
were anesthetized with 1.3% isoflurane (Abbott, Cham, Switserland) in a mixture of
oxygen/N2O (1:2) administered via a face mask. The body temperature of the mice
was kept at 37 degrees Celcius. No stereotactic holding was used. Measurements
were performed with a Biospec 47/40 spectrometer (Bruker, Medical Systems, Et-
tlingen, Germany) with field strength of 4.7 T, equipped with an actively shielded
gradient system. A (3D) gradient-echo sequence was used with the following imaging
parameters: TE=8ms, TR=40 ms, 2 averages, matrix=256Ö192Ö48, image resolu-
tion=2.8Ö7.5Ö30mm.
As objective we set to detect brain shape differences between the APP23 mice and
the controls. So, we adopted as null hypothesis:
H0 : There is no difference between the brains in APP23 mice and their controls
First, all images were normalized by an affine transform to correct for all non-
significant anatomical differences, as global orientation, global shape and brain. The
MR images were very noisy with low contrast in the brain, where only the ventricles
were clearly visible as shown in figure 6.4 (A and B).
To reduce the amount of misregistration that negatively influences the results
of the automated morphometry [41,42] a mask was created to extract the ventricles,
since the main objective of this study was to measure shape differences of the ventricle
area. Doing so, the registration algorithm was optimized for ventricle normalization,
87
Chapter 6
Figure 6.3: The estimated power for the influence of violations against the assumption





sizes N = 5 (A and B), N = 7 (C and D), N = 7 (E and F) and N = 20(G and H),
where the left column shows the displacement of one cloud in the x-direction and the
right column shows the displacement of a point clound in the y-direction.
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Figure 6.4: A slice from the 3D volume of a single control subject (A), the APP23
mouse (B), and the control average (C). Arrows indicate regions which show inhomo-
geneities, misregistration or incorrect masking. Furthermore, the region around the
ventricles is delineated as region of interest.
discarding all other brain areas. All mice were affine registered with mutual informa-
tion to an in-house developed mouse average. The normalization process resamples all
images to the same dimensions (X=160, Y=132, Z=255) and an isotropic voxel size
of 0.06mm, allowing voxel wise comparison between the different scans. Afterwards,
the whole brain is extracted from the image by masking the background, skull and
redundant brain tissue. The resulting average of the normalized wild types including
the mask for the region of interest (ROI) is shown in figure 6.4 (C). The white arrows
indicate regions outside the ROI that are misaligned in order to ensure the best fit for
the areas inside ROI. For this reason, all areas outside the ROI are therefore excluded
from further analysis. As a result, the null hypothesis changes to:
H0 : There is no difference between the ventricles areas in APP23 mice and their controls
As described in section 6.2.3, the formation of the average is a critical step in
the analysis. If the average is not from the same population as the control group,
the assumptions of spherical symmetry (thus intra-group variation and noise only)
might be violated. Therefore we generate the average from the control group itself.
As the sample sizes are small, a leave-1-out strategy was chosen for the warping
of the controls: Each control mouse was nonlinearly registered to the average of the
residuals. The APP23 mice were afterwards warped to the average of all controls. The
nonlinear registration was performed using the symmetric Demons algorithm [189], as
implemented in ITK [192]. The resulting vector fields of the Demons algorithm were
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used to test for group differences with the pHT2 and the MR3. In addition to that,
a one-sample Moore-Rayleigh test was applied on the two separate groups to screen
the deformation fields for violations against the assumptions.
Results
Figure 6.5 shows the result for the one sample case of Moore-Rayleigh test for the
controls and the APP23 mice overlayed on the average. Only voxels that are found
significant (α < 0.05) are overlayed on the average, for these voxels it is likely that
the assumptions of the MR3 are violated, i.e. are not spherically symmetric. The
image shows that the assumptions for spherical symmetry (assumption 1) holds for
most regions in the control brain, which justifies the application of the Moore-Rayleigh
test. The large amount of voxels for which the null hypothesis is rejected in the APP23
mice inside the ROI suggests already a group difference, which can be quantified by
the two-sample Moore-Rayleigh test.
The significant voxels that are located outside the ROI are possibly due to inten-
sity inhomogeneities or misregistration and are already excluded from the analysis.
However, the significant voxels that are located inside the ROI will not be tested with
the MR3 as indicated in section 6.2.3, but will be tested by permutation test with
the MR3 as test statistic as described in section 6.2.4.
Both the pHT2 and the MR3 were used to test the APP23 mice and their controls
for group differences. The results are shown in figure 6.6. Both test find similar
significant differences in the ventricle region. By comparing the p-values of the MR3
and the pHT2 in the ventricle region, we find significantly lower p-values for the MR3,
which are overall a factor 10 smaller compared to the pHT2. Calculation time on the
same computer for the MR3 and pHT2 was 10 minutes and 5 hours, respectively.
Figure 6.6 also demonstrates the effect of misregistration and image artifacts on
the results of morphometry. In the regions outside the ROI, especially in the cerebel-
lum (lower part of the image), large significant region is detected, that likely due to
misregistration and other image artifacts.
Generalization issues
To generalize the results from voxel level to brain level, multi-test correction has
to be applied. Bonferroni correction has the strongest control of the Type 1 er-
ror, leading to the least false positives. In this study the ventricles and surrounding
tissue were segmented from the volume (209,232 voxels), therefore Bonferroni cor-
rection results in a rejection of the H0 of equal ventricles if the p-value is smaller
than 0.05/209, 232 = 2 · 10−7 for one or more voxels inside the ROI. In the case of
Bonferroni correction, the MR3 has 34 significant voxels left, allowing the acceptance
of the alternative hypothesis that there is a difference in the ventricles of the APP23
mice and their controls. To achieve the same result with the permutation test, over
5,000,000 iterations are needed. Therefore other multiple-test correction method are
proposed, such using permutations [250] or the random field theory [45].
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Figure 6.5: The probability that a voxel is spherically symmetric for the wild types
(top row) and the APP23 mice (bottom row) for three different slices through the
brain. The area’s which were not found spherically symmetric at a significance level
of α < 0.05 were color coded by their p-value.
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In this study, generalization of the null hypothesis to the whole brain is not pos-
sible, as the registration is not optimal in regions other than the ventricles. In theory
however, if Bonferroni correction was applied for the whole brain (1.9 million voxels),
the p-values of some voxels in the ROI would still found significant after Bonferroni
correction of 2 · 10−9 = 0.05/1.9 · 106, i.e. 5 voxels for MR3 and therefore the null
hypothesis for shape difference in the whole brain between the APP23 mice and their
controls would be rejected.
6.4 Discussion
This work presents the nonparametric three-dimensional Moore-Rayleigh test (MR3)
as alternative test for permutation testing in deformation-based morphometry. The
results on simulated data show that the MR3 outperforms permutation tests on
Hotelling’s T 2 test (pHT2) in the detection of difference of mean in small sample
sizes, since the pHT2 has to estimate the covariance matrix from the data. The re-
sults on real data show that the MR3 and the pHT2 classify similar regions in the
brain as locally significant different, where MR3 has more power in detecting these
regions.
The p-value of permutation tests is limited for small sample sizes and by the
number of iterations, which explains the lower power for the pHT2 compared to the
MR3. But another important limitation of the pHT2 is that Hotelling’s T 2 test needs
to estimate the covariance matrix for the two groups of vectors, which might be
inaccurate for small sample sizes. As already shown in section 6.3.1, the power of the
MR3 is higher than the permutation test for small sample sizes as the MR3 has no
limit on its p-value and uses the whole vector information in contrast to permutation
testing and no covariance has to be estimated from the data by the Moore-Rayleigh
test. Permutations of the Hotelling’s T 2 test will only outperform the MR3 when the
violations against the assumptions are in the direction of the group differences. If the
tests are compared by power and speed, the MR test is outperforming the pHT2.
If the assumptions of the MR3 are violated, our results show that the Moore-
Rayleigh test fails gracefully and becomes more conservative. Interestingly, the op-
posite has been proven for the Wilcoxon signed-rank test, the equivalent of the one-
dimensional Moore-Rayleigh test. Violations against the assumptions of the Wilcoxon
signed-rank test will make the test excessively liberal [219, 220]. Since it is theoret-
ically expected that the MR3 might be liberal [249], an alternative test has been
proposed: If the assumptions of the MR3 are violated for a certain voxel, that voxel
is tested for significance differences by permutation testing with the MR3 as test
statistic.
In experimental data, the Moore-Rayleigh test has proven to be a powerful tool to
quantify group differences and the results are comparable to the permutation tests on
Hotelling’s T 2 statistics as currently used in human brain analysis [39]. Furthermore,
the regions detected by both tests are located on the areas of the ventricles that are
connected to either the hippocampus, the thalamus, or the caudoputamen, which
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correspond to the pathology of the APP23 mice [89].
The applicability of voxel wise discrimination methods is a topic for discussion
over the years. There are two main problems at the interpretation of voxel wise
morphometry:
First, registration errors influence the result and lead to incorrect rejections of
the the null hypothesis [41]. Therefore, it is recommended to validate statistical test
results on the data before reporting clinical implications [251]. Our findings on clinical
data confirms these statements, where the cerebellum region was not perfectly aligned
for some cases. This initial misregistration resulted in many false positives, found by
both the MR test and the pHT2. Already in previous work we found no significant
difference of significance detection by changing deformation algorithm [36], although
nonlinear registration algorithms differ in performance [252].
Secondly, generalizations of the conclusions at voxel level to structure level or even
brain level should be done with great caution [42]. The most important critic is that
voxels are assumed to be independent, while in fact they are correlated to each other.
From a statistical point of view, the generalization issues of voxel wise morphometry
can be interpreted as a multiple-hypotheses testing problem with a strong control
of the familywise error. The Bonferroni test has the strongest control of the type
1 error and is therefore the most reliable test for avoiding false positives. However
since most tests are dependent on relabelings of the permutations, other methods can
be applied [44]. Since the Moore-Rayleigh test is not bounded by relabelings it has
no lower bound on its p-values, which allows the application of Bonferroni correction.
Therefore, the conclusions of the MR test can be generalized in the safest way possible
to structure level and even to brain level.
In conclusion, we presented the 3D Moore-Rayleigh test as a single nonparametric
statistical test for deformation-based morphometry that offers an elegant alternative
for the computational expensive permutation testing. The test is not only faster to
compute, but also more suitable for small sample sizes and multiple-test correction
can be applied without problems.
6.4.1 Implementation
The code for the various MR tests in R and C++ have been made publicly available
at the website http://folk.ntnu.no/muskulus/.
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Figure 6.6: The probability per voxel that there is locally a group difference between
wild type mice and APP23 mice for three slices through the brain. The top row shows
the results from the permutations of the Hotelling’s T 2 test (pHT2) and the bottom
row shows the results from the single Moore-Rayleigh test (MR3). The area’s which
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abstract: Non-rigid registration of MR images to a common ref-
erence image results in deformation fields, from which anatomical
differences can be statistically assessed, within and between stud-
ies. Without further assumptions on the underlying distributions,
nonparametric tests are needed and usually the analysis of defor-
mation fields is performed by permutation tests. However, permu-
tation tests are computationally expensive and have limitations by
sample size and number of iterations. In this paper, we consider a
single nonparametric test as an alternative for permutation tests;
the 3D Moore-Rayleigh test. As its distribution function is avail-
able in closed form, permutation testing can be avoided. Further-
more, the test incorporates both the directions and magnitude of
the deformation vectors to attain a high power. Using synthetical
and clinical data we show the performance of the Moore-Rayleigh
test outperforms the classical permutation test and significantly
lowers the computational time as it is not dependent on the ran-
domization of the data.
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7.1 Introduction
Migraine is a neurological, paroxysmal disorder affecting up to 16% in the general
population. Patients suffer from throbbing, often unilateral headaches lasting 4 to
72 hours that are accompanied by nausea, vomiting and/or photo- and phonophobia
[253]. Of all migraine patients about one-third suffers from migraine with aura (MA),
characterized by an aura that consists of visual disturbances, but sensory-, motor-
or speech-related phenomena can occur as well [254]. Familial hemiplegic migraine
type-1 (FHM1) is an autosomal dominant subtype of MA, caused by mutations in the
CACNA1A gene. This gene encodes the pore forming 1-subunit of Cav2.1 (P/Q-type)
calcium channels.Catextsubscriptv2.1 channels open upon membrane depolarization,
allowing Ca2+ influx and subsequent neurotransmitter release.
Thus far, 3 FHM genes have been identified [255]. The FHM1 CACNA1A gene
encodes the pore-forming α1A-subunit of neuronal, voltage-gated Cav2.1 (previously
known as P/Q-type) calcium channels [256,257]. Two knock-in FHM1 mouse models,
one carrying the human pathogenic R192Q missense mutation [258,259], the other the
S218L CACNA1A mutation [260–262], were generated. In patients, the R192Q mu-
tation causes pure FHM without other associated neurological features [256], whereas
the S218L mutation causes a severe migraine phenotype with excessive and often fa-
tal cerebral edema [263]. When expressed in transfected cultured neurons, both mu-
tations shift channel opening toward more negative membrane potentials and delay
channel inactivation; the S218L mutation causes more pronounced single-channel gain
of function than R192Q [258,264]. As a result, channels open with smaller depolariza-
tion and stay open longer, allowing more Ca2+ to enter presynaptic terminals. FHM1
mouse models exhibit a reduced threshold for electrically evoked cortical spreading
disease (CSD) and increased SD velocity [259,265]. The S218L FHM1 mutation, but
not the R192Q FHM1 mutation, increased the probability of multiple CSD events in
response to only a single threshold stimulus. Whereas WT and R192Q mice generally
experienced a single CSD event on a single stimulus, the S218L mice showed a gene
dosage-dependent increased probability of having successive CSD events [262].
The neuropathology of MA patients shows some MRI abnormalities, like cerebellar
atrophia, thickening of the somatosensory cortex and sub-clinical white matter abnor-
malities in the cerebellum and brainstem correlating with attack frequency [266,267].
However, the nature of these MRI abnormalities is not known, and their relationship
to this disorder is still not well understood. In light of these findings in patients,
the present study investigates the morphological phenotypes of FHM1 mouse models,
using in vivo MRI in conjunction with semi-automated volumetry and deformation-
based morphometry [36] to quantify group differences. Thus, the goal of this inves-




Figure 7.1: The schematic protocol for post processing of the normalized MR images
for a cross-sectional study, so the two groups (control group and test group) can be
tested for local significant differences with the Moore-Rayleigh test.
7.2 Materials and methods
7.2.1 Specimen preparation
Female FHM1 mutant mice, homozygous for R192Q [259] or S218L [260] mutation
in the mouse Cacna1a gene (encoding the α1A pore-forming subunit of Cav2.1 chan-
nels), were compared with wild type (WT) littermates. The dataset consisted of 7
WT mice, 7 R192Q mice and 5 S218L mice at an age of 15.5 ± 2.5 months, 17.8
± 2.2 months and 12.6 ± 1.1 months, respectively. For in vivo MR imaging, mice
were initially anaesthetized with 4% isoflurane in O2/air (50/50%) and maintained
on 1.5% isoflurane during the procedure. The respiratory rate was monitored via
an air-pressure cushion and Biotrig software (Bruker, Rheinstetten, Germany). Af-
ter the MRI acquisitions, the brains were dehydrated and embedded into paraffin.
Hematoxylin-Eosin and Klüver-Barrera staining were performed on 5 µm-thick sec-
tions, using standard protocols. All animal handling and experiments were performed
in accordance with the guidelines of the universities and national legislation.
7.2.2 Magnetic resonance imaging
In vivo imaging of the mice in interictal state was performed on a Bruker 9.4 T
vertical 89-mm-bore magnet (Bruker BioSpin, Rheinstetten, Germany) with a Bruker
Micro2.5 gradient system and a transmit/receive birdcage radio frequency coil with
an inner diameter of 30 mm. Bruker ParaVision 3.0 software was used for image
acquisition. In vivo anatomical images were acquired using a T2-weighted multi-slice
spin echo sequence. Imaging parameters were: TE = 35 ms, TR = 6 s, FOV = 25.6
mm, matrix = 256Ö256, 40 slices of 0.2 mm thickness, with 4 averages. Total scan
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time was 102 minutes.
7.2.3 Histological evaluation
After MR imaging, the animals were sacrificied by intracardial perfusion with 4%
PFA and processed for standard histochemical staining with hematoxylin and eosin
and Klüver-Barrera. All sections were cut in coronal direction with a thickness of
5 µm.
7.2.4 Inspection correlated to human studies
First all in vivo MRI of the mice were visually examined for morphological abnormal-
ities by a mouse brain expert and a radiologist, both blinded for genotype. Special
attention was given to hyper- and hypointense lesions, as in human studies sub-clinical
white matter abnormalities in the cerebellum and brainstem correlate with attack fre-
quency. The comparison of histological brain tissue of R192Q mice S812L mice with
the wild types did not demonstrate any obvious structural abnormalities (not shown).
7.2.5 Image normalization
All in vivo MR images were normalized by affine registration (12 parameters) to
an in-house developed reference brain1 to correct for all non-significant anatomical
differences, such as global orientation, global shape and brain. The normalization
process resamples all images to the same dimensions (160Ö132Ö255) with an isotropic
voxel size of 56 µm, allowing voxel wise comparison between the different scans.
Afterwards, the whole brain is extracted from the image by masking the background,
skull and redundant head tissue. Unless otherwise specified, the normalized and
masked in vivo MR scans were used for all further analysis.
7.2.6 Automated morphometry
The three groups of mice were compared to each other (WT versus R192Q, WT
versus S218L and R192Q versus S218L) by deformation-based morphometry: For
each cross-sectional study, one group of mice was selected as control group defining
the baseline brain shape. The other group was considered as test group, which was
tested for equal brain size and shape relative to the control group. The process of
the preparation of the data is illustrated in figure 7.1. Average images were created
from the normalized MR images from control group for each cross-sectional study.
As the sample sizes were small, a leave-1-out strategy was chosen for the warping
of the controls to avoid correlations: Each control mouse was nonlinearly registered
to the average of the residuals. The normalized MR images of the test group were
afterwards warped to the average that was constructed from all control mice. The
nonlinear registration was performed using the symmetric Demons algorithm [189],
1An average created from in vivo MR images of 7 normalized C57Bl/6J mice.
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as implemented in itk [192]. The resulting vector fields indicate at each voxel the
spatial relationship to the corresponding voxel in the average. Statistical analysis was
applied to quantify group differences in the spatial displacement to the average at
voxel level by the application of the 3D Moore-Rayleigh test [36,249]. As a significant
group difference in spatial displacement implies a significant brain shape difference, we
defined hypotheses for the cross sectional studies: There is no brain shape difference
between:
1. the wild type R192Q mice (control group) and the R192Q mutants (test group)
2. the R192Q mutants (control group) and the S182L mutants (test group)
3. the wild type R192Q mice (control group) and the S182L mutants (test group)
As the significance detection was performed for each voxel independently, corrections
for multiple comparisons were required before conclusions can be generalized that
there are differences between the total brains of the groups. In this study, Bonferroni
multiple-test correct is applied, since Bonferroni correction has the strongest control
of the family-wise error rate, i.e. the probability that after correction for multiple-
tests still somewhere in the brain a false positive (an incorrect significant difference)
is detected. With this correction, the resulting p-values from the Moore-Rayleigh test
are adjusted by multiplication with the number of tests performed per cross-sectional
study (which equals the number of voxels in the normalized brain volume), while the
significance level α remains at 0.05.
7.2.7 Volumetry
As the nonlinear registrations were performed for each individual, volumetric mea-
surements were assessed by the segmentation of the three averages from the control
groups, as shown in figure 7.2. This segmentation is afterwards warped on top of the
individual subjects, after which the individual segmentations were manually corrected.
Volume measurements of the total ventricular space, the cortex, the hippocampus and
the cerebellum were performed by multiplying voxel-count by voxel size, which were
calculated as percentage of the total brain volume. Significant volume changes of
the brain structures were calculated by the nested Kruskal-Wallis test, which is the
nonparametric alternative for the MANOVA test.
7.3 Results
The first step was the visual inspection of the MR volumes and histological sections.
No morphologic abnormalities and clearly visible hyper- and hypointense lesions were
found (not shown). To detect any other significant differences between the brains
of the different groups, the volumes were analysed on a voxel-by-voxel basis using
deformation-based morphometry. With this test, some significant differences between
the brains were detected.
100
Quantitative morphometry on migraine mouse models
Figure 7.2: Volume rendering of the manual segmented cerebellum (green), the hip-
pocampal regions (purple), the cortex (yellow) and the ventricles (blue)
Figure 7.3: The deformation-based morphometry results for the three cross-sectional
studies. The statistical parametric map indicating the significance level per voxel for
three slices in the brain. The MR image is the average of each control group.
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Figure 7.3 shows the areas that are found significantly different between the three
groups. In the figure, three slices through the brain are overlapped on top of the
average of the control group. The significance level is indicated with a logarithmic
scale shown at the right hand side of the image, and coded in such a way that all
red voxels are found significant after Bonferroni multiple-test correction. Main sig-
nificantly different areas are found around the cerebellum, the hippocampal area, the
ventricles and some small areas in the brainstem. Figure 7.4 shows a volume rendering
of the brain with the areas indicated that are still found significant after Bonferroni
correction. In this figure, the ventricles are shown for a better visual interpretation
of the volume.
Based on these results, the MR images were again visually inspected to exclude any
type of MR artifacts or misregistration to avoid incorrect conclusions [41, 42]. Some
small discrepancies were detected in the averages of the MR images, as displayed
in Figure 7.5. It seems that the averaging of the subjects, introduced subtle image
intensity enhancing in the lower hippocampal regions and ventricular areas. Since
this image enhancement is not present in the single MR images, this might have
caused false positives in the hippocampal regions and the ventricles. The significant
areas in the cerebellum could not be explained by any visible discrepancies in the
MR images. Therefore, the averages of the different groups were placed side to side
to visually check for structural differences that could explain the significant areas.
Visual comparison of the averages shows a cerebellar shift in the caudal direction, as
shown in Figure 7.6.
This led us to a final analysis on the mouse brain, performed by traditional vol-
umetry on the structures that were found significant by DBM, i.e. cortex, cerebellum,
hippocampal area and the total ventricular space were segmented. The brainstem was
excluded for volumetry as it is located at the boundary of the image and can therefore
not be equally segmented for all images, leading to unreliable volumetry results. The
structures used for volumetry are shown in figure 7.2. The volumetric measurements
(in % of total brain volume) are listed in Table 7.1.
No significant differences were found between the groups for all structures with
the Kruskal-Wallis test (p-value = 0.16), therefore it was not statistically correct
to continue with testing the separate brain structures for group differences, thus no
significant structures can be reported based on volumetry.
Brain structure Wild type R192Q S218L
Cortex 30.37 ± 0.32 29.55 ± 0.44 31.23 ± 0.71
Cerebellum 10.89 ± 0.37 11.14 ± 0.26 10.84 ± 0.62
Hippocampus 5.10 ± 0.28 5.24 ± 0.17 5.26 ± 0.20
Ventricles 1.51 ± 0.31 1.54 ± 0.21 1.27 ± 0.14
Table 7.1: The normalized brain structure volumes expressed in % of the total brain
volume ± the standard deviations.
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Figure 7.4: A volume visualization of the regions that were found significant under
Bonferroni correction (red). For a better interpretation of the spatial orientation in
the brain, the ventricles are also shown (blue).
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Figure 7.5: A comparison of an MR slice of the control average and a regular subject.
The arrows indicate areas where some intensity enhancement due to the averaging
are visible.
7.4 Discussion
In this work, we morphologically validated the transgenic Cacna1a knockin strains as
migraine mouse model. Unbiased whole-brain analysis of in vivo MRI of FHM1 mice
using deformation-based morphometry combined with visual inspection of the volumes
showed a slight increase in cerebral volume and a caudal displacement. In addition,
with deformation field analysis, changes in the cerebellum, cortex and brainstem were
found. While at the same time, no large volumetric differences were detected in the
anatomy of the three groups.
So far, morphometry studies in human migraine patients show conflicting results:
One case-matched study reports no morphological changes between patients suffering
from migraine with aura (11 patients) and without aura(17 patients) [268], while
another case-matched study on 27 patients with migraine finds some minor significant
gray matter changes [269]. From both studies it can be concluded that the groups are
too small and heterogeneous to make any strong conclusion on significant structural
brain changes [270]. By the exploitation of transgenic mouse models, it is possible to
generate homogeneous groups that are highly suited for voxel-by-voxel morphometry
measurements. Since migraine is a functional disease where the number of anatomical
changes is correlated to the number of attacks, it is not surprising to find no significant
volumetric differences between the brain structures of the groups of mice, since the
sample sizes of the wild types (7 mice), R192Q mice (7 mice) and S218L mice (5
mice) were too small to detect any subtle volumetric differences between the brain
structures.
Using deformation-based morphometry, we found some significant areas in the
cortex, brainstem and cerebellum. Combined with visual inspection, a dorsal shift in
the cerebellum was found. Our results on volumetry show that displacement of the
cerebellum is probably not due to enlargement of the ventricles. In addition, volumet-
ric measurements on the cerebellum suggest an increased volume of the cerebellum in
R192Q mice, although the differences were not significant. Interestingly, subclinical
cerebellar impairment has been reported in migraine patients [271]. A later study on
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Figure 7.6: A visual comparison of the in vivo MR averages for each cross-sectional
study, showing the caudal shift of the cerebellum indicated with a white arrow.
cerebral volume in relation to migraine does not find an significant relation between
cerebral volume and patients with migraine with aura [272]. However, it is generally
accepted that the migraine aura is due to CSD, a wave of transient intense spike activ-
ity that progresses slowly along the cortex and is followed by a long-lasting neuronal
suppression [273–275]. In rodents, spreading depression can occur in the cortex, but
also in brainstem [276] and cerebellum [277]. Earlier results showed that both the
R192Q and S218L FHM1 mice exhibit an increased susceptibility to CSD [259]. CSD
induces blood-brain barrier disruption and can lead to edema in rats [278]. Therefore,
a possible explanation for this small cerebellar volume increase and caudal displace-
ment is edema, which is not visible on histological sections due to tissue fixation and
dehydration that precedes paraffin embedding.
Neuroimaging studies indicate that also the brainstem plays a role in migraine
[279–282]. An involvement of the brainstem is further supported by the fact that:
1) lesions in the brainstem can cause migraine [283–285]; 2) electrical stimulation of
the brainstem can cause headache [286, 287]; and 3) migraineurs have an increased
iron deposition in the brainstem Periaqueductal gray (PAG), possibly due to a high
metabolic activity in migraine [288]. In this study, deformation field analysis in
R192Q mice indicates morphological changes in the brainstem, specifically in the
region of the trigeminal nucleus caudalis (TNC), area postrema and nucleus tractus
solitarius (NTS). Moreover, trigeminovascular activation during a migraine attack
possibly triggers nausea and vomiting via activation of the nucleus tractus solitarius




In MA patients with high attack frequency, sub-clinical white matter abnormalities
were found particularly in regions of the cerebellum and brainstem [266, 267]. This
indicates that the migraine aura may be involved in the pathogenesis of these lesions.
We hypothesized that if lesions occur in FHM1 mice, lesion load would increase with
age. Therefore, we analyzed aged FHM1 mice. In this study, white matter MRI
abnormalities, similar to those found in migraine patients [267], were not found with
in vivo MRI investigations. However, the frequency of spontaneous attacks in these
mice is low (as in FHM1 patients), and most likely the low number of spontaneous
attacks in these mice during their relatively short lifespan is insufficient to cause
significant white matter damage. Also, the amount of white matter in mice is much
smaller than in humans, which may render the mouse model less vulnerable to white
matter damage.
MRI of migraine patients with and without aura also showed that migraineurs on
average have a thicker somatosensory cortex interictally2 than non-migraineurs [289].
The most significant thickness changes were noticed in the caudal somatosensory
cortex, where the trigeminal area, including head and face, is somatotopically rep-
resented3. To the best of our knowledge, no cortical thickness in the somatosensory
system has been measured in the FHM1 mice. In this study, some significant changes
in the caudal somatosensory cortex were reported by the deformation analysis al-
though it was also noted that some artifacts were present in the MR images. Future
somatosensory thickness measurements are required to confirm this observation of
somatosensory cortex changes in FHM1 mice.
In conclusion, our results show that the FHM1 mouse models are valuable models
to study migraine pathophysiology. In vivo MRI in combination with automated de-
formation analysis has the potential to facilitate longitudinal analysis of neuropathol-
ogy in vivo because live mice can be scanned on different occasions, allowing a natural
history of neuropathology rather than a single, terminal, time point.
2Interictal: between migraine attacks
3Somatotopical arrangement: The correspondence between the position of a receptor in any part
of the body and the corresponding area of the cerebral cortex that is activated by it. The size of the




8.1 Summary and conclusions
About 95% of the human DNA equals the DNA in mice and therefore, mice offer
a perfect environment to test new treatments, develop new screening procedures or
to apply experimental medications. To assist murine research, small-animal scanners
such as high-resolution CT or MR scanners are of considerable importance. Espe-
cially MR scanners are considered invaluable when studying the various aspects of
neuroanatomy, neuropathology and neurophysiology.
To assess group differences between mutants and their controls, brain morphome-
try can be exploited. As the morphological differences between the brains are subtle
and large groups are required for the analysis, automation of this analysis is inevitable.
Automated methods decrease the inter- and intra-observer variation, so that smaller
groups of mice are required to reach similar results as manual analysis. Unfortunately,
the development of automated image processing methods for high-resolutions images
lags behind the development of similar techniques in human research. This problem
mainly occurs because small-animal scanners were derived from human scanners and,
as a result, became available later in time; furthermore, high resolution images are
associated with higher noise levels.
The main objective of this thesis is to review existing automated methods for
quantitative morphometry of the murine brain and to develop new, repeatable and
fast automated methods for the detection of group differences using MR images.
In chapter 1 a general introduction on transgenic mice is given with a brief
history and a description of the ways transgenic mice can be generated. Further-
more the main differences and similarities between the human brain and the murine
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brain are described. Chapter 2 discusses which quantitative morphometry methods
can be exploited for mouse brain MRI and classifies them in volumetry, voxel-based
morphometry (VBM), shape-based morphometry (SBM) and deformation-based mor-
phometry (DBM). In connection with chapter 2, Chapter 3 indicates how automated
morphometry in mouse studies can assist in research to human diseases, in this case
Alzheimer’s Disease (AD). The characteristics of the most common lines of transgenic
mouse models and the various imaging techniques for AD in mice are discussed. It
indicates that the bulk of research on AD has been focussed on detecting and imag-
ing AD at earlier stages using MRI. Although an increasing number of publications
show the power of combining these imaging techniques with statistical analysis, the
application of automated morphometry methods in AD research in mice is still very
preliminary. The latter is remarkable since in human studies automated morphometry
is considered an established method.
Chapter 4 presents a fully automated segmentation method for several brain
structures in in vivo and ex vivo MRI to lower the burden of manual segmentation.
The method obtains an initial segmentation of the brain structures by applying affine
registration (12 parameters) to a manually delineated reference image. This initial
segmentation was further refined by a clustering algorithm, which used the structure
intensity and the presence of an image gradient in the neighborhood of the voxels. The
volumes of the automated segmentations were compared to the manual delineation
and the results of segmentation by nonlinear registration. The results show that
the proposed method had an equally good performance as manual segmentation and
nonlinear registration.
Chapter 5 presents a generalization to arbitrary dimensions of the nonparametric
Moore-Rayleigh test for randomness of vector data, as earlier presented by Moore for
two-dimensional vector data. For the three-dimensional Moore-Rayleigh test (MR3),
the asymptotic distribution in closed form and the two-sample MR3 were given to
allow the application of the MR3 for DBM. It was theoretically shown that the two-
sample MR3 might be potential liberal, although experiments on simulation data
and on synthetic data showed that the MR3 had equal performance as permutations
of the Hotelling’s T 2 test, a default method in human morphometry, although the
MR3 is not dependent on the computationally expensive permutations. Chapter 6
explores empirically the capabilities of the MR3 for the application of DBM and how
its performance compares to the performance of permutations on the Hotelling’s T 2
test (pHT2). Since the MR3 can be potential liberal and alternative approach for the
MR3 was presented. Experiments on simulated data and on mouse brain MRI showed
that the MR3 is suitable for DBM. Furthermore, because the p-value of the MR3 is
not limited by the number of relabelings, it allows multiple-test correction.Chapter
7 shows an application of the MR3, applied on two mouse models of migraine, the
R192Q knock-in mice and the S218L knock-in mouse. The MR3 was exploited to
screen the brain MR images for regional differences between the groups. The detected
locations were afterwards validated by volumetry on the brain structures and visual
inspection of histological sections.
The regional differences between the migraine mouse models and their wild types,
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as detected by the MR3, are in accordance with morphological findings in human
migraine studies, although no significant group differences between the brains were
detected by volumetry and no defects were found on histology.
In conclusion, quantitative and local morphometry of mouse brain MRI is a rel-
atively new field of research, where automated methods can be exploited to rapidly
provide accurate and repeatable results. In this thesis we reviewed several existing
methods and applications of quantitative morphometry to brain MR images and pro-
posed two new methods to quantitatively analyze mouse brain MRI. Both methods
have been validated and proved to be reliable, accurate and repeatable, without the
loss of computational time. Having said so, we have realized our goals stated in
section 1.4.
8.2 Future work
This thesis presents automated methods for quantitative morphometry in the mouse
brain by exploiting deformation fields. In this thesis it is assumed that the deformation
fields code for the anatomical differences between two images. In practise, however,
all nonlinear registration methods are validated on synthetically degenerated images
or by eyeball validation, as other methods are lacking. On that ground, we can only
conclude that these methods are capable of deforming an image so that it is similar
to another one, but it still remains unclear if brain tissue truly deforms as modeled
by nonlinear registration. Therefore further research on the validation of non-linear
registration is necessary.
With the introduction of automated methods, the processing time of image analy-
sis is decreased, and therefore other bottlenecks in mice research were addressed. For
example, coils for multiple-mouse imaging have been made available [56] and mice
centers with a capacity of 70.000 mice are being built1. However, this data-explosion
might have a negative effect on the results of automated morphometry. Morphometry
results are obtained by means of an image processing pipeline existing of a normal-
ization step, a feature extraction step and possibly other image processing steps, all
introducing their own sources of error. These errors might be visible in the deforma-
tion field as false positives. Therefore, it is still necessary to manually check all results
on possible errors introduced during the pipeline. Earlier detection and identification
of these errors during image processing will likely result in higher specificity. A pos-
sible solution for this problem is to develop computer aided methods in combination
with efficient visualization methods that point the user to the images or image areas
that might need manual correction. Good examples of these methods can be found
in human computer aided diagnostic (CAD) approaches [290,291], e.g. the screening
for lung tumors in X-ray images.
Finally, it would be recommended that for the development of future automated
morphometry methods multiple MR sequences should be used possibly in combina-
1Personal Communication of M. Sonka during the pre-meeting of the IEEE International Sym-
posium on Biomedical Imaging (ISBI) 2010, Rotterdam (13 April 2010).
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tion with statistical analysis, instead of adding extra imaging modalities. Although
currently more imaging techniques are being made available that all add extra infor-
mation to the analysis, the question remains if this extra information would lead to
more accurate morphometry results. Imaging of mice on several scanners introduces
extra intra-subject variations, either because the mice are transported between scan-
ners or, in case the mice remain anaesthetized and fixated during transport, because
extra stress and dehydration [180]. MRI is particularly suited for anatomical imag-
ing of soft tissue, does not use ionizing radiation and it is still maturing: Stronger
magnets, better coils and other hardware techniques are being made available and
will likely have a much larger impact on the quality and accuracy of morphometry,
as for instance already shown in brain segmentation [162] or in early Alzheimer’s de-
tection [77]. By further exploiting the wide range of possibilities that MR imaging,
offers automated quantitative morphometry will mature to a reliable and repeatable




9.1 Samenvatting en conclusies
Ongeveer 97.5% van het menselijk DNA is gelijk aan dat van de muizen. Daarom
bieden muizen een perfecte testomgeving om nieuwe behandelingen te testen, screen-
ingsprocedures te ontwikkelen, of om experimentele medicatie toe te passen. Om die
reden zijn muizenscanners, zoals hoge resolutie CT of MR scanners van groot be-
lang. Vooral de MR scanner wordt als zeer nuttig beschouwd als het aankomt op het
bestuderen van de verschillende aspecten van de hersenanatomie, hersenpathologie en
hersenfysiologie.
Om de verschillen tussen groepen van transgene muizen en de niet-transgene,
controle muizen te bepalen wordt gebruik gemaakt van hersenmorfometrie. Omdat
de morfologische verschillen tussen hersenen subtiel zijn en daardoor grote groepen
muizen nodig zijn om de significante verschillen aan te tonen, is het onvermijdelijk dit
proces te automatiseren. Dit heeft verder tot positief gevolg dat de inter- en intra-
observer variatie omlaag zal gaan, waardoor de kwantitatieve analyse nauwkeuriger
wordt en er minder muizen nodig zullen zijn om dezelfde resultaten te behalen als met
handmatige kwantitatieve analyse. Helaas loopt de ontwikkeling van automatische
beeldverwerkingsmethoden voor hoge resolutie beelden achter op de ontwikkeling van
dezelfde beeldverwerkingstechnieken voor humaan onderzoek. Dit is voornamelijk
doordat de scanners voor kleine dieren zijn ontwikkeld naar voorbeeld van humane
scanners; hierdoor kwamen deze scanners pas veel later beschikbaar. Daar komt bij
dat in een hogere beeldresolutie ook meer ruis aanwezig is.
Het hoofddoel van dit proefschrift is het in kaart brengen van bestaande automa-
tische kwantitatieve beeldverwerkingsmethoden voor muizenhersenen en om nieuwe,
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herhaalbare en snelle kwantitatieve morfometrie methoden voor de automatische de-
tectie van groepsverschillen van muizenhersenen opgenomen met de MR scanner te
ontwikkelen.
In hoofdstuk 1 wordt een algemene introductie over transgene muizen gegeven.
Er wordt kort ingegaan op de geschiedenis en de meest bekende methodes om trans-
gene muizen te ontwikkelen en de verschillen tussen mensen en muizenhersenen wor-
den kort gëıllustreerd. Hoofdstuk 2 behandelt de verschillende kwantitatieve mor-
fometrie methoden voor MR beelden van muizenhersenen, welke worden opgesplitst
in volumetrie, voxel-gebaseerde morfometrie (VBM), vorm-gebaseerde morfometrie
(SBM) en deformatie-gebaseerde morfometrie (DBM). Aansluitend op de algemene
introductie op morfometrie, geeft hoofdstuk 3 een voorbeeld hoe automatische mor-
fometrie bij muizenonderzoek kan helpen bij onderzoek naar humane ziektes, in dit
geval de ziekte van Alzheimer (AD). De karakteristieken van de meest gebruikelijke
muizenmodellen voor AD worden beschreven samen met de verschillende beeldvorm-
ingstechnieken om AD in de muizenhersenen aan te tonen. Het laat zien dat het
grootste gedeelte van onderzoek is gedaan naar visualisatie van de AD in een vroeg
stadium met MR scanners. Hoewel een groeiend aantal publicaties laat zien hoe
krachtig de combinatie van beeldvorming en statistische analyse kan zijn, staat de
ontwikkeling van automatische kwantitatieve morfometrie methoden echter nog in de
kinderschoenen. Het laatste is opmerkelijk omdat automatische morfometrie voor
humaan AD onderzoek al als een standaard methode wordt beschouwd.
In Hoofdstuk 4 wordt een volledig automatische segmentatie methode gepre-
senteerd van verschillende hersenstructuren in in vivo en ex vivo MR beelden om
de werkbelasting van de handmatige intekeningen te verlagen. Er wordt voorgesteld
om een initiële segmentatie van de structuren in de hersenen te verkrijgen door een
affine registratie (12 parameters) met een handmatig gesegmenteerde referentie beeld.
Daarna kan deze initiële segmentatie worden verfijnd door een clustering algoritme,
waarbij gebruik wordt gemaakt van voorkennis over de beeldintensiteit van de struc-
tuur en de locale beeldgradiënt. De volumes van de automatisch gesegmenteerde
structuren worden vergeleken met handmatige segmentaties en met segmentaties door
niet-lineaire registraties met een reeds ingetekend volume. De resultaten laten zien
dat de voorgestelde methode net zo goed presteert als handmatige segmentaties en
als niet-lineaire registratie.
In Hoofdstuk 5 wordt de Moore-Rayleigh test, een niet-parametrische test voor
de willekeurige verdeling van vector data, gegeneraliseerd van tweedimensionale vector
data naar vector data in elke mogelijke dimensie. Verder wordt de driedimensionale
Moore-Rayleigh test (MR3) in closed-form gegeven, samen met de MR3 voor twee
onafhankelijke groepen, waardoor de MR3 gebruikt kan worden voor DBM. Er wordt
theoretisch bewezen dat de MR3 voor twee groepen potentieel liberaal kan zijn, dat
betekent dat de test een grotere kans heeft om onterecht de nulhypothese te verw-
erpen.Echter, op gesimuleerde data wordt aangetoond dat de test in de praktijk net
zo goed presteert als een DBM methode gebaseerd op permutaties van de Hotelling’s
T2 test (pHT2), een standaard methode gebruikt bij beelden van het menselijk brein.
In tegenstelling tot the pHT2 is de MR3 niet afhankelijk is van de permutaties, die
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een lange berekeningstijd nodig hebben. In Hoofdstuk 6 worden de mogelijkheden
van de MR3 voor de toepassing voor DBM empirisch onderzocht en vergeleken met
de permutaties van de Hotellings T2 test. Experimenten op gesimuleerde data en
MR beelden van muizenhersenen tonen aan dat de MR3 geschikt is voor DBM. De
ondergrens van de p-waarde van de MR3 is, in tegenstelling tot permutatie testen,
niet gelimiteerd door het aantal permutaties dat wordt uitgevoerd, waardoor deze
test ook gebruikt kan worden als de p-waarden gecorrigeerd moeten worden voor het
gebruik van meerdere statistische testen. Hoofdstuk 7 laat een toepassing van de
MR3 op twee muismodellen voor migraine, de R192Q en de S218L knock-in muizen,
zien. De MR3 wordt gebruikt om de MR beelden van de hersenen te screenen op
afwijkingen die vervolgens door volumetrie en histologie verder worden onderzocht.
Hoewel de volumetrie metingen geen verschillen tussen de hersenstructuren laten zien
en op de histologie ook geen afwijkingen worden gevonden, zijn de lokale significante
gebieden in de hersenstructuren die door de MR3 worden gevonden wel te relateren
aan de morfometrische bevindingen van studies naar migraine bij mensen.
In conclusie, kwantitatieve en regionale morfometrie in MR beelden van muizen-
hersenen is een relatief nieuw onderzoeksgebied, waarbij automatische methodes ge-
bruikt worden om in weinig tijd objectieve, nauwkeurige en herhaalbare resultaten
te behalen. In dit proefschrift zijn verschillende bestaande morfometrie methodes
vergeleken en zijn twee nieuwe methodes voor morfometrie in MR beelden van muizen-
hersenen ontwikkeld. Beide methoden zijn gevalideerd en hebben bewezen betrouw-
baar, nauwkeurig en herhaalbaar te zijn zonder dat er tijd om het algoritme uit te
voeren lager is dan al bestaande algoritmen. Hiermee zijn de doelstellingen gehaald
zoals die in hoofdstuk 1.4 gedefinieerd zijn.
9.2 Aanbevelingen
Dit proefschrift presenteert automatische methoden voor kwantitatieve morphome-
trie in muizenhersenen die gebruik maken van deformatie velden. Hierbij wordt
aangenomen dat deze deformatie velden de anatomische verschillen tussen twee beelden
correct modelleren. Echter in de praktijk zijn alle bestaande niet-lineaire registratie
methoden, bij gebrek aan betere methoden, slechts gevalideerd op synthetisch verkre-
gen beelden of door middel van visuele validatie. Op basis van deze validatie kan
geconcludeerd worden dat deze methoden in staat zijn om een beeld zodanig te vervor-
men dat het precies op het andere past, maar of deze deformaties werkelijk hetzelfde
zijn als de deformaties zoals die in het hersenweefsel voorkomen blijft onduidelijk. Om
deze reden is verder onderzoek naar de validatie van niet-lineaire registratie noodza-
kelijk.
Nu de verwerkingstijd van de beeldanalyse omlaag is gegaan met de komst van
automatische beeldverwerkingsmethoden, worden andere knelpunten aangepakt. Zo
worden er bijvoorbeeld MR spoelen ontwikkeld waarbij meerdere muizen tegelijker-
tijd kunnen worden onderzocht [56] en worden er muizencentra met een capaciteit tot
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70.000 muizen opgezet1. Maar deze data-explosie kan een nadelig effect hebben op de
resultaten van de automatische morfometrie. De resultaten worden namelijk berek-
end via een keten van beeldverwerkings methoden, namelijk normalisatie, eventueel
registratie, extractie van de eigenschappen gebruikt voor classificatie, en andere beeld-
verwerkingstechnieken. Deze technieken introduceren allemaal hun eigen fouten. Deze
fouten zijn soms niet, maar vaak ook wel zichtbaar als een fout positieve uitslag van
de test. Daarom is het nog steeds noodzakelijk om handmatig alle resultaten te
controleren op mogelijke fouten die gëıntroduceerd zijn door de verschillende beeld-
verwerkings methoden. Bij een te grote dataset is er een kans dat dit achterwege
word gelaten of onnauwkeurig wordt gedaan. Het in kaart brengen van de invloed
van deze fouten en hun tijdige detectie zou de nauwkeurigheid van veel methodes
ten goede komen. Een mogelijke oplossing is om computer gestuurde methodes in
combinatie met efficiente visualisatie methoden te ontwikkelen om de gebruiker op de
beelden, of gebieden in de beelden, te wijzen die mogelijk een fout kunnen bevatten.
In een dergelijke setting hoeft alleen nog maar een subset van beelden handmatig
gecontroleerd te worden. Een goed voorbeeld van de werking van zulke methodes
is de toepassing van computer gestuurde diagnostische (CAD) systemen [290, 291],
bijvoorbeeld voor het screenen op long tumoren in röntgen beelden.
Een laatste aanbeveling gaat in de richting van het verder benutten van de MR
sequenties en de eventuele statistische analyse daarvan, in plaats van het toevoegen
van extra modaliteiten voor beeldanalyse. Hoewel met de huidige technieken steeds
meer scanners beschikbaar komen die allemaal extra informatie toevoegen aan de
analyse, is de vraag of dit de kwantitatieve morfometrie zou helpen. Het scannen van
muizen op verschillende toestellen introduceert ofwel extra intra-subject variatie bij
het verplaatsen ofwel extra stress en uitdroging voor muizen die worden verdoofd en
gefixeerd om de positie te behouden [180]. MRI is zeer geschikt voor het visualiseren
van zachte weefsels, het is niet schadelijk voor de gezondheid en het is nog steeds in
ontwikkeling. Sterkere magneten, betere spoelen en verbeterde hardware technieken
hebben waarschijnlijk een veel grotere impact op de kwaliteit en nauwkeurigheid van
morfometrie, zoals aangetoond in de segmentatie van de hersenen [162] of in de vroege
detectie van AD [77]. Het verder benutten van het brede toepassingsgebied van de MR
scanner zou de automatische kwantitatieve morfometrie kunnen helpen zich verder te
ontwikkelen tot een betrouwbare methode die in de dagelijkse routine gebruikt kan
worden.
1Persoonlijke communicatie van M. Sonka tijdens de officiële bijeenkomst ter introductie op de
IEEE International Symposium on Biomedical Imaging (ISBI) 2010, Rotterdam (13 April 2010).
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jzel, C.W.G.M. Löwik, J.H.C. Reiber, and B.P.F. Lelieveldt. Atlas-based whole-
body segmentation of mice from low-contrast Micro-CT data. Medical image analysis,
14(6):723–37, 2010.
[14] B. Dogdas, D. Stout, A.F. Chatziioannou, and R.M. Leahy. Digimouse: a 3D whole
body mouse atlas from CT and cryosection data. Physics in medicine and biology,
52(3):577–87, February 2007.
[15] M.H. Hofker and J. van Deursen. Transgenic mouse methods and protocols. Humana
Press, 2003.
[16] J.P. Sundberg and T. Ichiki. Genetically engineered mice handbook. CRC Press, 2006.
[17] A. Nagy, M. Gertsenstein, K. Vintersten, and R. Behringer. Production of Transgenic
Mice, chapter 7. Cold Spring Harbor Laboratory Press, 3rd edition, 2003.
[18] M.J. Tymms and I. Kola. Gene knockout protocols. Humana Press, 2001.
[19] G.S. Fisch and J. Flint. Transgenic and knockout models of neuropsychiatric disorders.
Humana Press, 2006.
[20] A. Lajtha, G.B. Baker, S. Dunn, and A. Holt. Handbook of neurochemistry and molec-
ular neurobiology: Practical neurochemistry methods. Springer, 3rd edition, 2007.
[21] M. Hafezparast, A. Ahmad-Annuar, N.W. Wood, S.J. Tabrizi, and E.M.C. Fisher.
Mouse models for neurological disease. Lancet neurology, 1(4):215–24, August 2002.
[22] B. Popko. Mouse Models in the Study of Genetic Neurological Disorders (Advances in
Neurochemistry). Springer, 1999.
[23] J.F. Cryan and A. Holmes. The ascent of mouse: advances in modelling human de-
pression and anxiety. Nature reviews. Drug discovery, 4(9):775–90, September 2005.
[24] I.N. Bankman. Segmentation, pages 71–258. USA: Academic Press, 2nd edition, 2009.
[25] K.J. Friston, A.P. Holmes, K.J. Worsley, J.P. Poline, and R. Frackowia. Statistical
parametric maps in functional imaging: a general linear approach. Human brain map-
ping, 2:189–210, 1995.
[26] K.J. Worsley, S. Marrett, P. Neelin, A.C. Vandal, K.J. Friston, and A.C. Evans. A
unified statistical approach for determining significant signals in images of cerebral
activation. Human brain mapping, 4(1):58–73, January 1996.
[27] J. Ashburner and K.J. Friston. Voxel-based morphometry - the methods. Neuroimage,
11(6 Pt 1):805–21, 2000.
[28] S.J. Sawiak, N.I. Wood, G.B. Williams, A.J. Morton, and T.A. Carpenter. Voxel-based
morphometry in the R6/2 transgenic mouse reveals differences between genotypes not
seen with manual 2D morphometry. Neurobiology of Disease, 33(1):20–27, 2009.
116
Bibliography
[29] L. Ferrarini, W.M. Palm, H. Olofsen, R. van Der Landen, M.A. van Buchem, J.H.C.
Reiber, and F. Admiraal-Behloul. Ventricular shape biomarkers for Alzheimer’s disease
in clinical MR images. Magnetic resonance in medicine, 59(2):260–7, February 2008.
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[260] K. Eikermann-Haerter, E. Dileköz, C. Kudo, S.I. Savitz, C. Waeber, M.J. Baum, M.D.
Ferrari, A.M.J.M. van Den Maagdenberg, M.A. Moskowitz, and C. Ayata. Genetic and
hormonal factors modulate spreading depression and transient hemiparesis in mouse
models of familial hemiplegic migraine type 1. The journal of clinical investigation,
119(1):99–109, January 2009.
[261] B. Todorov, R.C.G. van de Ven, S. Kaja, L.A.M. Broos, S.J. Verbeek, J.J. Plomp, M.D.
Ferrari, R.R. Frants, and A.M.J.M. van den Maagdenberg. Conditional inactivation
of the Cacna1a gene in transgenic mice. Genesis, 44(12):589–94, December 2006.
[262] A.M.J.M. van den Maagdenberg, T. Pizzorusso, S. Kaja, N. Terpolilli, M. Shapovalova,
F.E. Hoebeek, C.F. Barrett, L. Gherardini, R.C.G. van de Ven, B. Todorov, L.A.M.
Broos, A. Tottene, Z. Gao, M. Fodor, C.I. De Zeeuw, R.R. Frants, N. Plesnila, J.J.
Plomp, D. Pietrobon, and M.D. Ferrari. High cortical spreading depression suscepti-
bility and migraine-associated symptoms in Ca(v)2.1 S218L mice. Annals of neurology,
67(1):85–98, January 2010.
[263] E.E. Kors, G.M. Terwindt, F.L. Vermeulen, R.B. Fitzsimons, P.E. Jardine, P. Hey-
wood, S. Love, A.M.J.M. van den Maagdenberg, J. Haan, R.R. Frants, and M.D.
Ferrari. Delayed cerebral edema and fatal coma after minor head trauma: role of the
CACNA1A calcium channel subunit gene and relationship with familial hemiplegic
migraine. Annals of neurology, 49(6):753–60, June 2001.
[264] A. Tottene, T. Fellin, S. Pagnutti, S. Luvisetto, J. Striessnig, C. Fletcher, and
D. Pietrobon. Familial hemiplegic migraine mutations increase Ca(2+) influx through
single human CaV2.1 channels and decrease maximal CaV2.1 current density in neu-
rons. Proceedings of the national academy of sciences of the United States of America,
99(20):13284–9, October 2002.
[265] D. Pietrobon. Familial hemiplegic migraine. Neurotherapeutics, 4(2):274–84, April
2007.
[266] M.C. Kruit, L.J. Launer, M.D. Ferrari, and M.A. van Buchem. Brain stem and cere-
bellar hyperintense lesions in migraine. Stroke, 37(4):1109–12, April 2006.
[267] M.C. Kruit, M.A. van Buchem, P.A.M. Hofman, J.T.N. Bakkers, G.M. Terwindt, M.D.
Ferrari, and L.J. Launer. Migraine as a risk factor for subclinical brain lesions. the
journal of the American medical association, 291(4):427–34, January 2004.
[268] M.S. Matharu, C.D. Good, A. May, A. Bahra, and P.J. Goadsby. No change in the
structure of the brain in migraine: a voxel-based morphometric study. European
journal of neurology, 10(1):53–7, January 2003.
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